

GenCore version 5.1.3
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: February 24, 2003, 10:13:33 ; Search time 226.618 seconds
(without alignments)
10583.354 Million cell updates/sec

Title: US-09-922-895-2

Perfect score: 1065

Sequence: 1 ATGACACCTGACTAGATAC.....CGGAACCTCTATGTGTTT 1065

Scoring table: IDENTITY NUC
Gapop 10.0 , Gapext 1.0

Searched: 2185239 seqs, 112599159 residues

Total number of hits satisfying chosen parameters: 4370478

Minimum DB seq length: 0
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%
Maximum Match 100%

Listing first 45 summaries

Database :

N.Geneseq_101002:*
1: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1980.DAT:*
2: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1981.DAT:*
3: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1982.DAT:*
4: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1983.DAT:*
5: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1984.DAT:*
6: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1985.DAT:*
7: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1986.DAT:*
8: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1987.DAT:*
9: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1988.DAT:*
10: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1989.DAT:*
11: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1990.DAT:*
12: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1991.DAT:*
13: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1992.DAT:*
14: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1993.DAT:*
15: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1994.DAT:*
16: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1995.DAT:*
17: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1996.DAT:*
18: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1997.DAT:*
19: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1998.DAT:*
20: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1999.DAT:*
21: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA2000.DAT:*
22: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA2001A.DAT:*
23: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA2001B.DAT:*
24: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA2002.DAT:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB	ID	Description
1	1065	100.0	1068	21	AAF21266	Human low adenosis
2	1065	100.0	1068	21	AA35144	Human adenosis re
3	1065	100.0	1068	24	AAD2522	Human chemokine (C
4	1065	100.0	1193	17	AA731335	CC-chemokine recep
5	1065	100.0	1193	19	AAV07403	Human C-C chemok
6	1065	100.0	1201	21	AAF21267	Human low adenosis
7	1065	100.0	1201	21	AA35145	Human adenosis re
8	1065	100.0	1201	24	ABK84282	Human CDNA differe
9	1065	100.0	1717	24	ABL67066	Thyroid cancer rel

10	1065	100.0	1717	24	AAD25221	Human chemokine (C
11	1065	100.0	1915	18	AAF85162	Human chemokine re
12	1065	100.0	3958	21	AAF21269	Human low adenosis
13	1065	100.0	3958	21	AA35147	Human adenosis re
14	1065	100.0	5099	18	AA73601	Human eosinophil e
15	1064.2	99.9	1717	24	AAD25245	Human chemokine (C
16	1061.8	99.7	1068	23	AB197977	Non-endogenous hum
17	1061.8	99.7	1068	24	ABA94340	Human C-C chemokine
18	1061.8	99.7	1689	17	AA731334	CC-chemokine recep
19	1061.8	99.7	1689	18	AA758783	Human C-C chemok
20	1061.8	99.7	1689	19	AAV07402	Human C-C chemok
21	1061.8	99.7	1689	21	AAF21268	Human low adenosis
22	1061.8	99.7	1689	21	AA35146	Human adenosis re
23	1061.8	99.7	1689	24	ABL40462	Human C-C chemok
24	1053.8	98.9	1116	17	AA731335	CC-chemokine recep
25	1052.6	98.8	1116	19	AAV07404	Human C-C chemok
26	1039.2	97.6	1071	18	AA79096	Human CCR3 chemok
27	997	93.6	3426	24	ABT04010	Human ovary specif
28	713	66.9	7201	24	ABL32337	Human immune syste
29	637.8	59.9	7201	24	ABL32336	Human immune syste
30	540.8	50.8	1065	18	AA786154	Human MIP-1alpha/R
31	540.8	50.8	1495	15	AA062695	C-C chemokine rece
32	540.8	50.8	1495	21	AAF21264	Human low adenosis
33	540.8	50.8	1495	21	AA35142	Human adenosis re
34	540.8	50.8	2156	18	AA790384	Human MIP-1 alpha/
35	540.8	50.8	2156	21	AAF21258	Human low adenosis
36	540.8	50.8	2156	21	AAF21262	Human low adenosis
37	540.8	50.8	2156	21	AA35136	Human adenosis re
38	540.8	50.8	2156	21	AA35140	Human adenosis re
39	540.8	50.8	2214	24	ABK83592	Human CDNA differe
40	540.8	50.8	6606	21	AAF21265	Human low adenosis
41	540.8	50.8	6606	21	AA35143	Human adenosis re
42	487.2	45.7	1544	18	AA786839	CDNA encoding rat
43	363.4	34.1	1056	22	AAD13198	Human G-protein ch
44	363.4	34.1	1056	22	AAD13299	Human G-protein ch
45	363.4	34.1	1056	24	ABK51870	DNA encoding human

ALIGNMENTS

RESULT 1	
ID	AAF21266 standard; DNA; 1068 BP.
AC	AAF21266;
DT	14-MAR-2001 (first entry)
DE	Human low adenosis antisense oligonucleotide related sequence #2833.
XX	Human low adenosis antisense oligonucleotide; phosphorothioate; allergy;
KW	human; airway disorder; bronchoconstriction; lung inflammation;
KW	surfactant depletion; respiratory; bronchodilator; antiinflammatory;
KW	immunosuppressive; antisthmatic; analgesic; hypotensive; cyostatic;
KW	respiratory obstruction; pulmonary; hypotensive; hypotensive; hypotensive;
KW	surfactant hypoproduction; pulmonary vasodilation; asthma; RDS;
KW	respiratory distress syndrome; pain; cystic fibrosis; allergic rhinitis;
KW	pulmonary hypertension; emphysema; pulmonary transplantation rejection;
KW	chronic obstructive pulmonary disease; pulmonary infection; bronchitis;
KW	cancer; ss.
OS	Homo sapiens.
XX	
PN	WO200062736-A2.
XX	
PD	26-OCT-2000.
XX	
PF	24-MAR-2000; 2000WO-US08020.
XX	
PR	06-APR-1999; 99US-0127958.
XX	
PA	(UYEC-) UNIV EAST CAROLINA.

PF 03-AUG-1999; 99WU-US17712.
XX
XX 03-AUG-1998; 98US-0095212.
XX
PA (UYEC-) UNIV EAST CAROLINA.
XX
XX Myce JW;
XX
XX WPI: 2000-205971/18.
DR
XX
XX New antisense oligonucleotides useful for treating e.g. pulmonary
PT vasocostriction, inflammation, allergies, asthma, hypertension,
PT bronchitis, emphysema, respiratory distress syndrome, ischemia or
PT cancers -
XX
XX
PS Disclosure: Page 1102; 1343pp; English.

XX The present invention describes a new composition comprising an
CC antisense oligonucleotide (ON) with low adenosine (up to 15%), which
CC targets nucleic acids involved in bronchoconstriction, allergies, and/or
CC inflammation. The ON can have antiinflammatory, antiallergic,
CC antitasthmatic, cytostatic and analgesic activities. The compositions are
CC useful for the treatment of diseases associated with inflammation,
CC impaired airways, including lung disease and diseases whose secondary
CC effects afflict the lungs of a subject. They can be used for treating
CC e.g. ischemic conditions, pulmonary vasoconstriction, allergies,
CC asthma, impaired respiration, respiratory distress syndrome, pain, cystic
CC fibrosis, pulmonary hypertension, emphysema, chronic obstructive
CC pulmonary disease (COPD), and cancers such as leukemias, lymphomas,
CC carcinomas, and cancers which may metastasize to the lungs, including
CC breast and prostate cancer. The reduction of the adenosine content of
CC the ONs reduces side effects. The A-containing ONs break down with the
CC release of deoxyadenosine which activates adenosine receptors causing
CC bronchoconstriction and inflammation. AAA32313 to AAA35312 represent the
CC nucleotide sequences given in the sequence listing from the present
CC invention, which correspond to SEQ ID NO:1 to 2815, and then the last
CC 185 sequences are also called SEQ ID NO:1 to 185, but the sequences
CC differ from the previously named sequences. SEQ ID NO:11 to 1680
CC (AAA32323 to AAA33992) are specifically claimed ONs from the present
CC invention. N.B. Sequences given in the disclosure of the present
CC invention do not match up with their corresponding SEQ ID NO: sequences
CC given in the sequence listing.
XX

XX Sequence 1068 BP; 231 A; 289 C; 243 G; 305 T; 0 other;

Query Match 100.0%; Score 1065; DB 21; Length 1068;
Best Local Similarity 100.0%; Pred. No. 1.6e-313;
Matches 1065; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ATGACAACTCACTAGATACAGTTCAGACCTTGGTACACATCTCTATGATGACGTG 60
DB 1 ATGACAACTCACTAGATACAGTTCAGACCTTGGTACACATCTCTATGATGACGTG 60
QY 61 GGCCTGCTCTGTGAAAAGCTGATACAGACGACGTGATGGCCAGTTGTGCCCGCGCTG 120
DB 61 GGCCTGCTCTGTGAAAAGCTGATACAGACGACGTGATGGCCAGTTGTGCCCGCGCTG 120
QY 61 GGCCTGCTCTGTGAAAAGCTGATACAGACGACGTGATGGCCAGTTGTGCCCGCGCTG 120
DB 61 GGCCTGCTCTGTGAAAAGCTGATACAGACGACGTGATGGCCAGTTGTGCCCGCGCTG 120
QY 121 TACTCCCTGCTTCACTGTGGGCTCTGGGCAATGTGGTGTGATGATCCCTCATA 180
DB 121 TACTCCCTGCTTCACTGTGGGCTCTGGGCAATGTGGTGTGATGATCCCTCATA 180
QY 181 AATATACAGAGGCTCCGAATATGACCAACATCTACCTGCTCAACTGGCCATTTTGGAG 240
DB 181 AATATACAGAGGCTCCGAATATGACCAACATCTACCTGCTCAACTGGCCATTTTGGAG 240
QY 241 CTGCTCTTCTCTGTACACCTTCCATTCTGATGACACTATGATGAGGGGCAATACTGGGTT 300
DB 241 CTGCTCTTCTCTGTACACCTTCCATTCTGATGACACTATGATGAGGGGCAATACTGGGTT 300
QY 301 TTGAGCATGGGATGTGTAAGCTCTCTCAGGGTTTATACACAGAGCTTGTACAGCGAG 360
DB 301 TTGAGCATGGGATGTGTAAGCTCTCTCAGGGTTTATACACAGAGCTTGTACAGCGAG 360

QY 361 ATCTTTTTCATATATCCCTGCTGACAATGACAGCTACCTGGCCATTGCTCATCTGTGTTT 420
DB 361 ATCTTTTTCATATATCCCTGCTGACAATGACAGCTACCTGGCCATTGCTCATCTGTGTTT 420
QY 421 GCCCTTTCGAGCCCGGAGCTGTCACTTTTGGTGTATCACCAGCATGCTACCTGGGGCTTG 480
DB 421 GCCCTTTCGAGCCCGGAGCTGTCACTTTTGGTGTATCACCAGCATGCTACCTGGGGCTTG 480
QY 481 GCAGTGTGACGAGCTCTTCCGAATTTATCTTATGACAGCAAGAGTGTGTTGAAGG 540
DB 481 GCAGTGTGACGAGCTCTTCCGAATTTATCTTATGACAGCAAGAGTGTGTTGAAGG 540
QY 541 ACTCTTTGCAAGTCTCTTTTACCCAGAGATACAGTATATAGCTGGAGGATTTCCACACT 600
DB 541 ACTCTTTGCAAGTCTCTTTTACCCAGAGATACAGTATATAGCTGGAGGATTTCCACACT 600
QY 601 CTGAGATGACCATCT 660
DB 601 CTGAGATGACCATCT 660
QY 661 GGAATCATCAAAAGCTGCTGAGAGTGGCCAGTAAAGTAAAGTAAAGTAAAGTAAAGTAAAG 720
DB 661 GGAATCATCAAAAGCTGCTGAGAGTGGCCAGTAAAGTAAAGTAAAGTAAAGTAAAGTAAAG 720
QY 721 ATTTTGTATCATGAGCGGTGTTTTCATTTCTGACACCTTACATGTGGCTATCTT 780
DB 721 ATTTTGTATCATGAGCGGTGTTTTCATTTCTGACACCTTACATGTGGCTATCTT 780
QY 781 CTCTCTCTATCATCATCTCTTATTTGGAATGACTGTGACGCGAGCAAGCATCTGAC 840
DB 781 CTCTCTCTATCATCATCTCTTATTTGGAATGACTGTGACGCGAGCAAGCATCTGAC 840
QY 841 CCGGTATCTCTGTGACAGAGTGAATGCGCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 900
DB 841 CCGGTATCTCTGTGACAGAGTGAATGCGCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 900
QY 901 TACGCTTTTGTGAGAGAGTTCGGAAGTACCTGCGCACCTTCTCCACAGGACCTTG 960
DB 901 TACGCTTTTGTGAGAGAGTTCGGAAGTACCTGCGCACCTTCTCCACAGGACCTTG 960
QY 961 CTGATGACCTTGGGAGATATCCATTCCTTCCAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAG 1020
DB 961 CTGATGACCTTGGGAGATATCCATTCCTTCCAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAG 1020
QY 1021 TCTGTCTCTCAATCCACAGACAGAGCGGAGCACTCTATGTGTTT 1065
DB 1021 TCTGTCTCTCAATCCACAGACAGAGCGGAGCACTCTATGTGTTT 1065

RESULT 3
AAD25222
ID AAD25222 standard; cDNA; 1068 BP.
XX
XX AAD25222;
XX
XX 12-MAR-2002 (first entry)
XX
XX Human chemokine (C-C motif) receptor 3 (CCR3) cDNA.
XX
XX Human; chemokine (C-C motif) receptor 3; CCR3 gene; haplotyping;
KW genotyping; type IV hypersensitivity reaction; HIV-1; gene therapy;
KW human immunodeficiency virus 1; single nucleotide polymorphism; SNP;
KW chromosome 3p21.3; ss.
XX
OS Homo sapiens.
XX
XX Key Location/Qualifiers
FH replace (51, C)
FT variation
FT /*tag= a
FT /*standard_name= "Single nucleotide polymorphism (SNP)"
FT /*note= "Polymorphic site (ps) 3"
FT 1..1068
FT /*tag= b

FT	variation	/product="Human CCR3 protein"
FT		replace (1052, C)
FT		/tag= C
FT		/standard.name="Single nucleotide polymorphism (SNP)"
FT		/note="Polymorphic site (PS) 4"
PN	MO200187908-AZ.	
PD	22-NOV-2001.	
XX		
XX	18-MAY-2001; 2001WO-US16278.	
PF		
XX	18-MAY-2000; 2000US-205191P.	
PR		
PA	(GENA-) GENA15520.	
PI	Choi JY, Kazemi A, Koshiy B;	
XX		
XX	WPI: 2002-055681/07.	
DR	P-PSDB; AA015320.	
XX		
PT	Isolated polymorphic variants of chemokine (C-C motif) receptor 3	
PT	(CCR3) gene useful for studying function of CCR3, expressing the CCR3	
PT	protein and to screen drugs to treat CCR3 activity-related diseases -	
XX		
PS	Claim 25a; Fig 2; 53pp; English.	
XX		
CC	The invention relates to genetic variants of human chemokine (C-C motif)	
CC	receptor 3 (CCR3) gene. The invention also relates to compositions and	
CC	methods for haplotyping and/or genotyping the CCR3 gene in an individual.	
CC	Polynucleotides of the invention are useful for studying the expression	
CC	and function of CCR3 and in expressing CCR3 proteins for use in screening	
CC	candidate drugs to treat diseases related to CCR3 activity. They are also	
CC	used in gene therapy. The polymorphism and haplotype data is useful for	
CC	validating whether CCR3 is a suitable target for drugs to treat type IV	
CC	hypersensitivity reactions and human immunodeficiency virus (HIV)-1.	
CC	screening for such drugs and reducing bias cells in clinical trials of	
CC	such drugs. The genotyping method is useful for determining whether an	
CC	individual has one haplotype or haplotype pairs. The haplotyping method	
CC	is useful for improving the efficiency and outcome of several steps in	
CC	the discovery and development of drugs for treating diseases associated	
CC	with CCR3 activity such as type IV hypersensitivity reactions and HIV-1.	
CC	The present sequence is human CCR3 cDNA. The CCR3 gene is located on	
CC	chromosome 3p21.3.	
XX		
SQ	Sequence 1068 BP; 231 A; 289 G; 243 G; 305 T; 0 other;	
XX		
Query Match	100.0%; Score 1065; DB 24; Length 1068;	
Best Local Similarity	100.0%; Pred. No. 1.6e-313;	
Matches 1065; Conservative	0; Mismatches 0; Indels 0; Gaps 0	
OY	1 ATGACAACTCTACTGATACAGTTGAGACCTTTGGTACCAACATCCATATGATGACGCG 60	
DB	1 ATGACAACTCTACTGATACAGTTGAGACCTTTGGTACCAACATCCATATGATGACGCG 60	
OY	61 GGCCTGCTCTGTGAAAAAGCTGATACAGACAGCACTGATGAGCCAGTTTGTGCCCGCGTG 120	
DB	61 GGCCTGCTCTGTGAAAAAGCTGATACAGACAGCACTGATGAGCCAGTTTGTGCCCGCGTG 120	
OY	121 TACCTCCGCTGCTTACAGCTGTGGCCCTTTGGGCAATGCTGCTGATATGATCCCTCA 180	
DB	121 TACCTCCGCTGCTTACAGCTGTGGCCCTTTGGGCAATGCTGCTGATATGATCCCTCA 180	
OY	181 AAATACAGAGAGCTCCGATTTATGACCAACATCTACCTGCAACCTGGCCATTTTGGGAC 240	
DB	181 AAATACAGAGAGCTCCGATTTATGACCAACATCTACCTGCAACCTGGCCATTTTGGGAC 240	
OY	241 CTGCTCTTCTCTGTCACCTTTCATTTCTGGATTCACATATGACAGGGGGCATTAAGTGGTT 300	
DB	241 CTGCTCTTCTCTGTCACCTTTCATTTCTGGATTCACATATGACAGGGGGCATTAAGTGGTT 300	
OY	301 TTTGGCATGCGATGTATAGCTCCTCTGAGGGTTTATACACAGAGCTTGTACACGAG 360	
DB	301 TTTGGCATGCGATGTATAGCTCCTCTGAGGGTTTATACACAGAGCTTGTACACGAG 360	

	Db	301	TTTGGCCATGGCAGTGCTAAGCTCCTCTCAGGGTTTATACACAGCGCTTACAGCGAG	360
Qy	361	ATCTTTTTCATATATCGTGTGACAAATGCAGAGGTACCTGGCAATGTCCATGCTGTGTTT	420	
Db	361	ATCTTTTTCATATATCGTGTGACAAATGCAGAGGTACCTGGCAATGTCCATGCTGTGTTT	420	
Qy	421	GCCCTTGAGCCCGGCACTGTACCTTTTGGTGCATACACAGCATGTCTACCTGGGGCCCTG	480	
Db	421	GCCCTTGAGCCCGGCACTGTACCTTTTGGTGCATACACAGCATGTCTACCTGGGGCCCTG	480	
Qy	481	GCATGCTAGACAGCTCTTCCATGATTTATCTTATGAGACTGAAGAGTGTGTTAAAG	540	
Db	481	GCATGCTAGACAGCTCTTCCATGATTTATCTTATGAGACTGAAGAGTGTGTTAAAG	540	
Qy	541	ACTCTTTGCAGCTCTTTTACCAGAGGATACGATATATAGCTGAGGCAATTTCCACACT	600	
Db	541	ACTCTTTGCAGCTCTTTTACCAGAGGATACGATATATAGCTGAGGCAATTTCCACACT	600	
Qy	601	CTGGAATGACCATCTTCTGTCTCTGCTTCCCTCTGCTCTGTTATGGCCATCTGCTACACA	660	
Db	601	CTGGAATGACCATCTTCTGTCTCTGCTTCCCTCTGCTCTGTTATGGCCATCTGCTACACA	660	
Qy	661	GGATTCATCAAAAACGGCGTGAAGTGGCCCGCCAGTAAAAAAAATACAAAGGCCATCCGGCTC	720	
Db	661	GGATTCATCAAAAACGGCGTGAAGTGGCCCGCCAGTAAAAAAAATACAAAGGCCATCCGGCTC	720	
Qy	721	ATTTTTCATCATCAGCGGCGTGTTTTCATTTTCTGAGACACCCATACATGTGGCTATCCTT	780	
Db	721	ATTTTTCATCATCAGCGGCGTGTGTTCATTTTCTGAGACACCCATACATGTGGCTATCCTT	780	
Qy	781	CTCTCTTCATCATCATTCATCTTATTTTGGAAATGACTGTGAGCGGAGCAAGCATGTGCAC	840	
Db	781	CTCTCTTCATCATCATTCATCTTATTTTGGAAATGACTGTGAGCGGAGCAAGCATGTGCAC	840	
Qy	841	CTGTCATGCGTGGGAGACAGAGGTGATGCGCCTATCTCCATCGTGCATGAACCGGTGATC	900	
Db	841	CTGTCATGCGTGGGAGACAGAGGTGATGCGCCTATCTCCATCGTGCATGAACCGGTGATC	900	
Qy	901	TAGCCCTTTGTTGGAGAGAGGTTCCGGAAATACCTGCGCACCTTCTTCCACAGGCACCTTG	960	
Db	901	TAGCCCTTTGTTGGAGAGAGGTTCCGGAAATACCTGCGCACCTTCTTCCACAGGCACCTTG	960	
Qy	961	CTCATGCACTGGGCGAGATACATCCATCTTCTTCTAGTGAAGAGCTGGAAAGAACCGAC	1020	
Db	961	CTCATGCACTGGGCGAGATACATCCATCTTCTTCTAGTGAAGAGCTGGAAAGAACCGAC	1020	
Qy	1021	TCTGCTCTCCATCCACAGAGAGCGGAAACTCTCATTTGTGTTT	1065	
Db	1021	TCTGCTCTCCATCCACAGAGAGCGGAAACTCTCATTTGTGTTT	1065	
RESULT 4				
AAT31335				
DD	AAT31335 standard; cDNA; 1193 BP.			
XX	AAT31335;			
XX	15-NOV-1996 (first entry)			
XX	CC-chemokine receptor 3 cDNA clone.			
DE				
XX	CC-chemokine receptor 3; CCR-3; Eos-12; inhibitor; antisense;			
KW	antiinflammatory; eosinophil; ss.			
XX	Homo sapiens.			
OS				
XX	Key			
FH	Location/Qualifiers			
FT	CDS			
FT	variation			
FT	/*lag- a			
FT	918..919			
FT	/*lag- b			
FT	/note= "CCR-3 cDNA clone has GC at positions			
FT	918-919, coding for serine (AGC) at			

XX (LEUK-) LEUKOSITE INC.
 XX Mackay CR, Ponath PD;
 PI WPT: 1998-286418/25.
 XX P-PSDB: AAW51745.
 XX
 XX Antibodies to chemokine receptor-3 protein - useful for diagnosis
 PT and treatment of inflammatory conditions, e.g. allergy, asthma,
 PT autoimmune disease, graft rejection or cancer
 XX
 XX Example 8, Page 134-136; 185pp: English.

XX This cDNA codes for novel human C-C chemokine receptor 3 (see
 XX AAW51745), also designated CKR-3, CCR3 or Eos I2, that binds and
 XX mediates chemotaxis in response to chemokines such as eotaxin,
 XX RANTES and MCP-3. The cDNA was isolated from a human eosinophil
 XX cDNA library constructed from eosinophils obtained from a patient
 XX with hypereosinophilic syndrome, and using CKR-1 cDNA as probe. A
 XX genomic DNA sequence (see AAW07402) is also provided as well as a
 XX consensus sequence (see AAW07404) for CKR-3. The invention relates
 XX to isolated and/or recombinant nucleic acids encoding CKR-3,
 XX isolated or recombinant CKR-3 polypeptides, recombinant nucleic
 XX acid constructs, host cells useful for production of recombinant
 XX CKR-3 proteins, to antibodies reactive with the receptors, and to
 XX methods of using these products to identify ligands, antagonists
 XX and agonists of receptor function. Inhibitors of CKR-3 can be used
 XX to treat: inflammatory or allergic diseases and conditions,
 XX including respiratory allergic diseases such as asthma, allergic
 XX rhinitis, hypersensitivity lung disease, hypersensitivity
 XX pneumonitis, eosinophilic pneumonia (e.g. Loeffler's syndrome,
 XX chronic eosinophilic pneumonia, interstitial lung disease (ILD)
 XX e.g. idiopathic pulmonary fibrosis or ILD associated with
 XX rheumatoid arthritis, systemic lupus erythematosus, ankylosing
 XX spondylitis, systemic sclerosis, Sjogren's syndrome, polyositis
 XX or dermatomyositis), systemic anapylaxis or hypersensitivity
 XX responses, drug allergy, insect sting allergy, inflammatory bowel
 XX disease, such as Crohn's disease and ulcerative colitis,
 XX spondyloarthritis, scleroderma, psoriasis, inflammatory
 XX dermatosis such as dermatitis, eczema, atopic dermatitis,
 XX allergic contact dermatitis, urticaria, vasculitis (e.g. necrotizing,
 XX cutaneous and hypersensitivity vasculitis); eosinophilic myositis
 XX and eosinophilic fasciitis; autoimmune diseases such as rheumatoid
 XX arthritis, psoriatic arthritis, multiple sclerosis, systemic lupus
 XX erythematosus, myasthenia gravis, juvenile onset diabetes,
 XX glomerulonephritis, autoimmune thyroiditis and Behcet's disease;
 XX graft rejection, including allograft rejection or graft-versus-host
 XX disease; cancers with leukocyte infiltration of the skin or organs;
 XX and also reperfusion injury, atherosclerosis, certain haematologic
 XX malignancies, septic shock and endotoxic shock. Promoters of CKR-3
 XX function can be used for treating: immunosuppression e.g. in AIDS
 XX patients or individuals undergoing radiation therapy, chemotherapy,
 XX therapy for autoimmune disease or other drug therapy, and
 XX immunosuppression due to congenital deficiency in receptor function or
 XX other causes; and infectious diseases such as parasitic diseases,
 XX including helminth infections, such as nematodes (round worms).
 XX The agents can also be used for detection and diagnosis.
 XX
 XX Sequence 1193 BP; 274 A; 310 C; 275 G; 334 T; 0 other;

Query Match 100.0%; Score 1065; DB 19; Length 1193;
 Best Local Similarity 100.0%; Pred. No. 1.6e-313;
 Matches 1065; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ATGACAACTCATAGATAGAGACCTTGGTACCACTCCTACTATGATGACGTG 60
 DB 92 ATGACAACTCATAGATAGAGACCTTGGTACCACTCCTACTATGATGACGTG 151
 QY 61 GGCCTGCTGTGAAAGAGTATACAGACACTGATGGCCAGTTGGCCCGCGCTG 120
 DB 152 GGCCTGCTGTGAAAGAGTATACAGACACTGATGGCCAGTTGGCCCGCGCTG 211

QY 121 TACTCCCTGCTGCTTACAGTGTGGCCCTCTTGGCAATGTGTGTGTATGATCCCTCAT 180
 DB 212 TACTCCCTGCTGCTTACAGTGTGGCCCTCTTGGCAATGTGTGTGTATGATCCCTCAT 271
 QY 181 AATATACAGAGGCTCCGAATTATGACCAACATCTACCTGCTCAACCTGGCCATTTCGGAC 240
 DB 272 AATATACAGAGGCTCCGAATTATGACCAACATCTACCTGCTCAACCTGGCCATTTCGGAC 331
 QY 241 CTGCTCTTCCTGCTGACCTTCCATTCGATGACCACTATGTGAGGGGGCATTAATGGGTT 300
 DB 332 CTGCTCTTCCTGCTGACCTTCCATTCGATGACCACTATGTGAGGGGGCATTAATGGGTT 391
 QY 301 TTTGGCCATGGCATGTGTAAAGCTCTCTCAGAGGTTTATACACAGCGCTTGTACAGCGAG 360
 DB 392 TTTGGCCATGGCATGTGTAAAGCTCTCTCAGAGGTTTATACACAGCGCTTGTACAGCGAG 451
 QY 361 ATCTTTTATATATCTGTGTACATTCGACAGGTACCTGCGCATTTGTCCATCTGTGTTT 420
 DB 452 ATCTTTTATATATCTGTGTACATTCGACAGGTACCTGCGCATTTGTCCATCTGTGTTT 511
 QY 421 GGCCTTCGAGCCCGGACCTGTCACTTTTGGTGTATCACCAGCATGTCACCTGGGGCGCTG 480
 DB 512 GGCCTTCGAGCCCGGACCTGTCACTTTTGGTGTATCACCAGCATGTCACCTGGGGCGCTG 571
 QY 481 GCAGTGTACAGACCTCTCTCTTAATTTATCTTGTATGAGACTGAAAGATTGTTGAAGAG 540
 DB 572 GCAGTGTACAGACCTCTCTCTTAATTTATCTTGTATGAGACTGAAAGATTGTTGAAGAG 631
 QY 541 ACTCTTGTGAGAGCTCTTATACCAAGAGATATAGTGTGAGAGGATTTCCACACT 600
 DB 632 ACTCTTGTGAGAGCTCTTATACCAAGAGATATAGTGTGAGAGGATTTCCACACT 691
 QY 601 CTGAGATGACCATCTCTCTCTGCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 660
 DB 692 CTGAGATGACCATCTCTCTCTGCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 751
 QY 661 GGAATCATCAAAACGCTGCTGAGGTGCCCCAGTAAAGAAATACAGAGCATCCGGCTC 720
 DB 752 GGAATCATCAAAACGCTGCTGAGGTGCCCCAGTAAAGAAATACAGAGCATCCGGCTC 811
 QY 721 ATTTTGTATATAGGCGGTGTTTTCATTTCTGAGACCCCTACAAATGTGCTATCCCT 780
 DB 812 ATTTTGTATATAGGCGGTGTTTTCATTTCTGAGACCCCTACAAATGTGCTATCCCT 871
 QY 781 CTCTCTTCCATCAATCCATCTTATTTGGAATGACTGTGACGAGCAAGCATCTGGAC 840
 DB 872 CTCTCTTCCATCAATCCATCTTATTTGGAATGACTGTGACGAGCAAGCATCTGGAC 931
 QY 841 CTGTGATGCTGTGTACAGAGGTATGCTTCCACTGCTGCTGATGAACCCGGTATC 900
 DB 932 CTGTGATGCTGTGTACAGAGGTATGCTTCCACTGCTGCTGATGAACCCGGTATC 991
 QY 901 TACGCTTGTGTGAGAGAGGTCCGAGATACCTGCGCATCTTCCACAGGGACATTG 960
 DB 992 TACGCTTGTGTGAGAGAGGTCCGAGATACCTGCGCATCTTCCACAGGGACATTG 1051
 QY 961 CTCATCCACCTGGGAGATATATCCATCTCTTCTAGTGAAGCTGGAAGAAACACAGC 1020
 DB 1052 CTCATCCACCTGGGAGATATATCCATCTCTTCTAGTGAAGCTGGAAGAAACACAGC 1111
 QY 1021 TCTGTCTTCATCCACAGAGAGCCGGAAGCTCTATTTGTGTTT 1065
 DB 1112 TCTGTCTTCATCCACAGAGAGCCGGAAGCTCTATTTGTGTTT 1156

RESULT 6
 AAF21267
 ID AAF21267 standard; DNA; 1201 BP.
 XX AAF21267;
 AC
 XX
 DT 14-MAR-2001 (first entry)

DE Human low adenosine antisense oligonucleotide related sequence #2834.
XX Low adenosine antisense oligonucleotide; phosphorothioate; allergy;
XX human; airway disorder; bronchoconstriction; lung inflammation;
KM surfactant depletion; respiratory; bronchodilator; antiinflammatory;
KM immunosuppressive; antisthmatic; analgesic; hypotensive; cytoskeletal;
KM surfactant obstruction; pulmonary obstruction; impeded respiration;
KM surfactant hypoproduction; pulmonary vasoconstriction; asthma; RDS;
KM respiratory distress syndrome; pain; cystic fibrosis; allergic rhinitis;
KM pulmonary hypertension; emphysema; pulmonary transplantation rejection;
KM chronic obstructive pulmonary disease; pulmonary infection; bronchitis;
KM cancer; ss.
XX Homo sapiens.
XX MO200062736-A2.
XX 26-OCT-2000.
XX 24-MAR-2000; 2000WO-US08020.
XX 06-APR-1999; 99US-0127958.
XX (UYEC-) UNIV EAST CAROLINA.
XX (NYCE/) NYCE J W.
XX Nyce JW:
XX WPI: 2000-679539/66.
XX Low adenosine (A) content antisense oligonucleotides which do not
PT trigger adenosine receptors during metabolism, useful e.g. for treating
PT cancers and respiratory obstructions -
XX
XX Disclosure: Page 1182-1183; 1592pp; English.
XX
XX The present invention describes low adenosine (A) content antisense
CC oligonucleotides and compositions (I) comprising them. In the antisense
CC oligonucleotides the A is replaced by a 'universal' or alternative base.
CC (I) can have respiratory, bronchodilator, antiinflammatory, analgesic,
CC immunosuppressive, antisthmatic, hypotensive and cytoskeletal activities.
CC The antisense oligonucleotides and (I) can be used to down-regulate the
CC expression and/or activity of target polypeptides associated with
CC lung/respiratory disorders and malignancies, such as stimulating and
CC activating peptide factors and transmitters, transcription factors,
CC immunoglobulins and antibodies, antibody receptors, cytokines and
CC chemokines, endogenously produced specific and non-specific enzymes,
CC binding proteins, adhesion molecules and their receptors, cytokine and
CC chemokine receptors, adenosine receptors, bradykinin receptors, central
CC nervous system (CNS) and peripheral nervous and non-nervous system
CC receptors, CNS and peripheral nervous and non-nervous system peptide
CC transmitters, defensins, growth factors, vasoreactive peptides and
CC receptors, binding proteins and malignancy associated proteins. The
CC antisense oligonucleotides may be used in this way to treat disorders
CC including respiratory obstruction (especially pulmonary obstruction
CC and/or bronchoconstriction) and/or lung inflammation, allergy(ies)
CC and/or surfactant hypoproduction which are associated with a disease or
CC condition selected from pulmonary vasoconstriction, inflammation,
CC allergies, asthma, impeded respiration, respiratory distress syndrome
CC (RDS), pain, cystic fibrosis (CF), allergic rhinitis (AR), pulmonary
CC hypertension, emphysema, chronic obstructive pulmonary disease (COPD),
CC pulmonary transplantation rejection, pulmonary infections, bronchitis,
CC and/or cancer. AAF18434 to AAF21543 represent human polynucleotide
CC fragments and antisense oligonucleotides used in the exemplification of
CC the present invention.
XX
XX Sequence 1201 BP; 278 A; 320 C; 267 G; 336 T; 0 other;
SQ

Query Match 100.0%; Score 1065; DB 21; Length 1201;
Best Local Similarity 100.0%; Pred. No. 1.7e-31;
Matches 1065; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ATGACAACCTCAGTACAGTTGAGACCTTTGGTACACATCTACTATGATGACGTG 60

|||||
Db 32 ATGACAACCTCAGTACAGTTGAGACCTTTGGTACACATCTACTATGATGACGTG 91
QY 61 GCGCTGCTCTGTATAAAGCTGTATACAGAGCAGTATGAGCCAGTTTGCCCGCGTG 120
Db 92 GCGCTGCTCTGTATAAAGCTGTATACAGAGCAGTATGAGCCAGTTTGCCCGCGTG 151
QY 121 TACTCCGTGTGTTCACTGTGGGCTTGGGCAATGTGGTGGATGATCTCATTA 180
Db 152 TACTCCGTGTGTTCACTGTGGGCTTGGGCAATGTGGTGGATGATCTCATTA 211
QY 181 AAATACAGAGGCTCCGAATTTATGACCAACATCTACCTGCTCAACCTGGCCATTTGGAC 240
Db 212 AAATACAGAGGCTCCGAATTTATGACCAACATCTACCTGCTCAACCTGGCCATTTGGAC 271
QY 241 CTGCTCTCTCTGTACACCTTCTGATCTGATCCATATGTACAGGGGCAATTAAGTGGTT 300
Db 272 CTGCTCTCTCTGTACACCTTCTGATCTGATCCATATGTACAGGGGCAATTAAGTGGTT 331
QY 301 TTTGGCCATGAGCATGTGTAGCTCTCTGAGGTTTATACACAGGCTTGTACAGGAG 360
Db 332 TTTGGCCATGAGCATGTGTAGCTCTCTGAGGTTTATACACAGGCTTGTACAGGAG 391
QY 361 ATCTTTTTCATATCTGCTGACATTCAGAGGTACCTGGGCAATTTGCTATGCTGTGTTT 420
Db 392 ATCTTTTTCATATCTGCTGACATTCAGAGGTACCTGGGCAATTTGCTATGCTGTGTTT 451
QY 421 GCCCTTGAGCCCGGAGCTGTCACTTTTGTGTATCAGCAGCATCTGACCTGGGCGCTG 480
Db 452 GCCCTTGAGCCCGGAGCTGTCACTTTTGTGTATCAGCAGCATCTGACCTGGGCGCTG 511
QY 481 GCAGTCTGACAGCTCTCTCTGAAATTTATCTATGAGCTGAAAGTGTGTTGAAGAG 540
Db 512 GCAGTCTGACAGCTCTCTCTGAAATTTATCTATGAGCTGAAAGTGTGTTGAAGAG 571
QY 541 ACTCTTTGAGCTCTCTTACCAGAGATACATATATGCTGAGAGGCTTTCCACACT 600
Db 572 ACTCTTTGAGCTCTCTTACCAGAGATACATATATGCTGAGAGGCTTTCCACACT 631
QY 601 CTGAGATGACCATCTTCTGTCTGCTTCTGCTGCTGCTTATGGCATCTGCTACACA 660
Db 632 CTGAGATGACCATCTTCTGTCTGCTTCTGCTGCTGCTTATGGCATCTGCTACACA 691
QY 661 GGAATATCAAAACGCTGCTGAGGCTGCGCCAGTAAAGTAAAGGCAATCCGGGCTC 720
Db 692 GGAATATCAAAACGCTGCTGAGGCTGCGCCAGTAAAGTAAAGGCAATCCGGGCTC 751
QY 721 ATTTTGTCTATGAGCGGCTTTTCTATTTCTGGACACCTTACATATGCTATCTTT 780
Db 752 ATTTTGTCTATGAGCGGCTTTTCTATTTCTGGACACCTTACATATGCTATCTTT 811
QY 781 CTCTCTTCTATGATCATCTTATTTTGAATGACTGTGAGGAGCAAGCATCTGGAC 840
Db 812 CTCTCTTCTATGATCATCTTATTTTGAATGACTGTGAGGAGCAAGCATCTGGAC 871
QY 841 CTGCTATGCTGTGACAGAGGATGCTGCTTCTCCACATCTGCAATGAAACCGGATGATC 900
Db 872 CTGCTATGCTGTGACAGAGGATGCTGCTTCTCCACATCTGCAATGAAACCGGATGATC 931
QY 901 TAGCCCTTTGTTGAGAGAGGTTCCGGAAGTACCTGCGCCTTCTTCCACAGGCACTTT 960
Db 932 TAGCCCTTTGTTGAGAGAGGTTCCGGAAGTACCTGCGCCTTCTTCCACAGGCACTTT 991
QY 961 CTGATGACCTGGGCAAGATATCATCCATCTTCTCTAGTGAAGAGCTGGAAGAACCCAGC 1020
Db 992 CTGATGACCTGGGCAAGATATCATCCATCTTCTCTAGTGAAGAGCTGGAAGAACCCAGC 1051
QY 1021 TCTGTCTCTCATCCACAGAGAGCGGGAACCTCTATTTGTGTTT 1065
Db 1052 TCTGTCTCTCATCCACAGAGAGCGGGAACCTCTATTTGTGTTT 1096

RESULT 7

AAA35145
ID AAA35145 standard: DNA: 1201 BP.
XX
AC AAA35145:
XX
DT 28-JUL-2000 (first entry)
XX
DE Human adenosine receptor related polynucleotide 2nd SEQ ID NO:19.
XX
XX Human: adenosine receptor; low adenosine antisense oligonucleotide;
KM phosphorothioate; impaired respiration; inflammation; allergy;
KM allergic diseases; bronchoconstriction; inhibitor; antinflammatory;
KM antiallergic; antialsthmatic; cyclostatic; analgesic; impaired airway;
KM lung disease; ischemic condition; pulmonary vasoconstriction; asthma;
KM respiratory distress syndrome; pain; cystic fibrosis; emphysema;
KM pulmonary hypertension; chronic obstructive pulmonary disease; COPD;
KM cancer; leukemia; lymphoma; carcinoma; metastasis; ss.
XX
OS Homo sapiens.
XX
PN MO200009525-A2.
XX
PD 24-FEB-2000.
XX
PF 03-AUG-1999; 99WO-US17712.
XX
PR 03-AUG-1998; 98US-0095212.
XX
PA (UYEC-) UNIV EAST CAROLINA.
XX
XX Nlyce JW;
XX
DR WPI; 2000-205971/18.
XX
PT New antisense oligonucleotides useful for treating e.g. pulmonary
PT vasoconstriction, inflammation, allergies, asthma, hypertension,
PT bronchitis, emphysema, respiratory distress syndrome, ischemia or
PT cancers -
XX
PS Disclosure: Page 1102; 1343pp; English.
XX
XX The present invention describes a new composition comprising an
CC antisense oligonucleotide (ON) with low adenosine (up to 15%), which
CC targets nucleic acids involved in bronchoconstriction, allergies, and/or
CC inflammation. The ON can have antinflammatory, antiallergic,
CC antisthmatic, cyclostatic and analgesic activities. The compositions are
CC useful for the treatment of diseases associated with inflammation,
CC impaired airways, including lung disease and diseases whose secondary
CC effects afflict the lungs of a subject. They can be used for treating
CC e.g. ischemic conditions, pulmonary vasoconstriction, allergies,
CC asthma, impaired respiration, respiratory distress syndrome, pain, cystic
CC fibrosis, pulmonary hypertension, emphysema, chronic obstructive
CC pulmonary disease (COPD), and cancers such as leukemias, lymphomas,
CC carcinomas, and cancers which may metastasize to the lungs, including
CC breast and prostate cancer. The reduction of the adenosine content of
CC the ONs reduces side effects. The A-containing ONs break down with the
CC release of deoxyadenosine which activates adenosine receptors causing
CC bronchoconstriction and inflammation. AAA32313 to AAA3512 represent the
CC nucleotide sequences given in the sequence listing from the present
CC invention, which correspond to SEQ ID NO:1 to 2815, and then the last
CC 185 sequences are also called SEQ ID NO:1 to 185, but the sequences
CC differ from the previously named sequences. SEQ ID NO:11 to 1880
CC (AAA33323 to AAA33992) are specifically claimed ONs from the present
CC invention. N.B. Sequences given in the disclosure of the present
CC invention do not match up with their corresponding SEQ ID NO: sequences
CC given in the sequence listing.
XX
XX
SQ Sequence 1201 BP; 278 A; 320 C; 267 G; 336 T; 0 other;

Query Match 100.0%; Score 1065; DB 21; Length 1201;
Best Local Similarity 100.0%; Pred. No. 1.7e-313;
Matches 1065; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY	1	ATGACAACTCAGTAGATAGATGAGACCTTGGTACACATCTCAATGATGACGTG	60
DB	32	ATGACAACTCAGTAGATGAGACCTTGGTACACATCTCAATGATGAGACGTG	91
QY	61	GGCCTGCTCTGTGAAAAAGCTGATACAGACACTGATGGCCAGTTTGTCGCCCGCTG	120
DB	92	GGCCTGCTCTGTGAAAAAGCTGATACAGACACTGATGGCCAGTTTGTCGCCCGCTG	151
QY	121	TACCTCCCTGGTGTTCACATGTGGGGCTTGGGCAATGTGGTGGGATGATCTCATTA	180
DB	152	TACTCCCTGGTGTTCACATGTGGGGCTTGGGCAATGTGGTGGGATGATCTCATTA	211
QY	181	AAATACAGAGAGGCTCCGAATATGACCAACATCTACCTGCTCAACCTGGCCATTTGGAC	240
DB	212	AAATACAGAGAGGCTCCGAATATGACCAACATCTACCTGCTCAACCTGGCCATTTGGAC	271
QY	241	CTGCTCTCTCTGCTGACACCTTCCATTTGTCATGCATATGTCAAGGGGCAATACTGGTT	300
DB	272	CTGCTCTCTCTGCTGACACCTTCCATTTGTCATGCATATGTCAAGGGGCAATACTGGTT	331
QY	301	TTTGGCCATGGCATGTGTAGACTCTCTCAGGGTTTATACACAGGCTGTACAGGAG	360
DB	332	TTTGGCCATGGCATGTGTAGACTCTCTCAGGGTTTATACACAGGCTGTACAGGAG	391
QY	361	ATCTTTTTCATTAATCTCTGTCAGACATGACAGGATGACCTGGCCATTTGCTGTGTTT	420
DB	392	ATCTTTTTCATTAATCTCTGTCAGACATGACAGGATGACCTGGCCATTTGCTGTGTTT	451
QY	421	GCCCTTGAGACCCGGAGCTGTACCTTTGGTGTATACACAGCATCTGACACTGGGGCTG	480
DB	452	GCCCTTGAGACCCGGAGCTGTACCTTTGGTGTATACACAGCATCTGACACTGGGGCTG	511
QY	481	GCAAGTCTACAGAGCTCTCTCTGAATTTATCTCTATGAGACTGAAGAGTTTGAAGAG	540
DB	512	GCAAGTCTACAGAGCTCTCTCTGAATTTATCTCTATGAGACTGAAGAGTTTGAAGAG	571
QY	541	ACTCTTTCAGAGTGTCTTTTACCCAGAGATACAGTATAGCTGAGAGCAATTTCCACACT	600
DB	572	ACTCTTTCAGAGTGTCTTTTACCCAGAGATACAGTATAGCTGAGAGCAATTTCCACACT	631
QY	601	CTGGAATGACATCT	660
DB	632	CTGGAATGACATCT	691
QY	661	GGAATTCATCAAAAGCGCTGAGGTGCGCCAGTAAAAAAGTACAAAGGCAATCCGGCTC	720
DB	692	GGAATTCATCAAAAGCGCTGAGGTGCGCCAGTAAAAAAGTACAAAGGCAATCCGGCTC	751
QY	721	ATTTTGTTCATCATGCGGGTGTCTTTCATTTTCTGACACCTTCAATGTGGCTATCTT	780
DB	752	ATTTTGTTCATCATGCGGGTGTCTTTCATTTTCTGACACCTTCAATGTGGCTATCTT	811
QY	781	CTCTCTTCATCATATTCATCTTATTTGGAAATGACGTGAGGGGAGCAAGCATCTTGAC	840
DB	812	CTCTCTTCATCATATTCATCTTATTTGGAAATGACGTGAGGGGAGCAAGCATCTTGAC	871
QY	841	CTGTCATGCTGGGAGAGAGAGTATGCTTACCTCCACAGCTGTCATGAAGACCGGATATC	900
DB	872	CTGTCATGCTGGGAGAGAGAGTATGCTTACCTCCACAGCTGTCATGAAGACCGGATATC	931
QY	901	TACGCTTTTGTGAGAGAGGTTCCGAAATACCTGCGCCATCTTTCACAGGCACTTG	960
DB	932	TACGCTTTTGTGAGAGAGGTTCCGAAATACCTGCGCCATCTTTCACAGGCACTTG	991
QY	961	CTCATGACCTGGGAGAGATATATCCATTTCTTCTGTAGTGAAGAGCTGGAAGAACACAGC	1020
DB	992	CTCATGACCTGGGAGAGATATATCCATTTCTTCTGTAGTGAAGAGCTGGAAGAACACAGC	1051
QY	1021	TCGTCTCTCCATCCACAGAGAGCCGGAACCTCTTATGTGTTT	1065
DB	1052	TCGTCTCTCCATCCACAGAGAGCCGGAACCTCTTATGTGTTT	1096

RESULT 8
ABK84282
ID ABRK4282 standard: cDNA; 1201 BP.
XX
AC ABRK4282;
XX
XX 14-AUG-2002 (first entry)
XX
DE Human cDNA differentially expressed in granulocytic cells #853.
XX
XX Human; ss; granulocytic cell; DNA chip; bacterial infection;
KM viral infection; parasitic infection; protozoal infection;
KM fungal infection; sterile inflammatory disease; psoriasis;
KM rheumatoid arthritis; glomerulonephritis; asthma; thrombosis;
KM cardiac reperfusion injury; renal reperfusion injury; ARDS;
KM adult respiratory distress syndrome; inflammatory bowel disease;
KM Crohn's disease; ulcerative colitis; periodontal disease;
KM granulocyte activation; chronic inflammation; allergy.
XX
OS Homo sapiens.
XX
PN W0200228999-A2.
XX
PD 11-APR-2002.
XX
XX 03-OCT-2001; 2001WO-US30821.
XX
XX 03-OCT-2000; 2000US-237189P.
XX
PR (GENE-) GENE LOGIC INC.
XX
PA Beazer-Barclay Y, Weissman SM, Yamaga S, Vockley J;
PI WPI: 2002-435328/46.
XX
DR
XX
XX
PT Detecting granulocyte activation by detecting differential expression
PT of genes associated with granulocyte activation, which serves as
PT diagnostic markers that is useful for monitoring disease states and
PT drug toxicity -
XX
XX
PS Claim 1: SEQ ID No 853; 114pp: English.
XX
XX The invention relates to detecting (M1) granulocyte (GC) activation
CC (GCA), by detecting the level of expression of gene(s) (Gs) identified by
CC DNA chip analysis as given in the specification, and comparing
CC the expression level to an expression level in an unactivated
CC GC, where differential expression of Gs is indicative of GCA.
CC Also included are modulating (M2) GA by contacting GC with an agent
CC that alters the expression of at least one gene in Gs; (2) screening (M3)
CC for an agent capable of modulating GCA or an inflammation (especially
CC chronic) in a tissue, an allergic response in a subject, exposure of a
CC subject to a pathogen or sterile inflammatory disease using the
CC gene expression profile; (3) detecting (M4) an inflammation (especially
CC chronic) in a tissue, an allergic response in a subject, exposure of a
CC subject to a pathogen or sterile inflammatory disease, by detecting the
CC level of expression in a sample of the tissue of gene(s) from Gs, where
CC the level of expression of the gene is indicative of inflammation;
CC (4) treating (M5) an inflammation (especially chronic) or in a tissue,
CC an allergic response in a subject, exposure of a subject to a pathogen
CC or sterile inflammatory disease, by contacting a tissue having
CC inflammation with an agent that modulates the expression of gene(s)
CC from Gs in the tissue. M1 is useful for detecting GCA; M2 is useful for
CC modulating GA; M3 is useful for screening an agent capable of modulating
CC GCA preferably in an inflammation in a tissue; M4 is useful for
CC detecting an inflammation (especially chronic) in a tissue, an allergic
CC response in a subject, exposure of a subject to a pathogen or sterile
CC inflammatory disease (e.g. psoriasis, rheumatoid arthritis,
CC glomerulonephritis, asthma, thrombosis, cardiac reperfusion injury, renal
CC reperfusion injury, ARDS, adult respiratory distress syndrome,
CC inflammatory bowel disease, Crohn's disease, ulcerative colitis,
CC periodontal disease; also bacterial infection, viral infection,
CC parasitic infection, protozoal infection, fungal infection and M5 is
CC useful for treating one of the above conditions. The present

CC sequence represents a gene differentially expressed in granulocytes.
CC Note: The sequence data for this patent did not form part
CC of the printed specification, but was obtained in electronic
CC format directly from WIPO at
CC ftp.wipo.int/pub/published_pcl_sequences.
XX
XX
SQ Sequence 1201 BP; 278 A; 320 C; 267 G; 336 T; 0 other;
Query Match 100.0%; Score 1065; DB 24; Length 1201;
Best Local Similarity 100.0%; Pred. No. 1.7e-313;
Matches 1065; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
1 ATGACACACTCTACATGATACAGTTGAGACCTTGGTACACATCTCTACATGATGACG 60
DB |||||||
32 ATGACACACTCTACATGATACAGTTGAGACCTTGGTACACATCTCTACATGATGACG 91
DB |||||||
61 GGCCTGCTCTGTGAAAAAGCTGATACAGAGCAGTATGAGCCAGTTTGGCCCCGCTG 120
DB |||||||
92 GGCCTGCTCTGTGAAAAAGCTGATACAGAGCAGTATGAGCCAGTTTGGCCCCGCTG 151
DB |||||||
121 TACTCCCTGCTGTACCTGCTGCGCCCTTGGGCAATGTGGTGTGATGATCCCTCAT 180
DB |||||||
152 TACTCCCTGCTGTACCTGCTGCGCCCTTGGGCAATGTGGTGTGATGATCCCTCAT 211
DB |||||||
181 AATACAGAGAGCTCCGATTTATGACCAATCTACCTGCTCACTGGCCATTTCGAC 240
DB |||||||
212 AATACAGAGAGCTCCGATTTATGACCAATCTACCTGCTCACTGGCCATTTCGAC 271
DB |||||||
241 CTGCTCTCTGCTGACCTTCCATTTCTGATCTACATGTCAGGGGCAATACGCTGTT 300
DB |||||||
272 CTGCTCTCTGCTGACCTTCCATTTCTGATCTACATGTCAGGGGCAATACGCTGTT 331
DB |||||||
301 TTTGGCCATGAGATGATGTAAGCTCCCTGAGGTTTATACACAGAGCTTGTACAGCG 360
DB |||||||
332 TTTGGCCATGAGATGATGTAAGCTCCCTGAGGTTTATACACAGAGCTTGTACAGCG 391
DB |||||||
361 ATCTTTTTCATATCTCTGCTGACATGACAGGTACCTGGCAATTTCCATGCTGTGTT 420
DB |||||||
392 ATCTTTTTCATATCTCTGCTGACATGACAGGTACCTGGCAATTTCCATGCTGTGTT 451
DB |||||||
421 GCCCTTGAGCCGGGAGCTGTACCTTTTGGTGTATACACAGATCTGTACCTGGGCTG 480
DB |||||||
452 GCCCTTGAGCCGGGAGCTGTACCTTTTGGTGTATACACAGATCTGTACCTGGGCTG 511
DB |||||||
481 GGAGTCTGAGAGCTCTCTGCTGATTTATCTCTATGACATGAAAGTGTGTTGAAG 540
DB |||||||
512 GGAGTCTGAGAGCTCTCTGCTGATTTATCTCTATGACATGAAAGTGTGTTGAAG 571
DB |||||||
541 ACTCTTTGAGAGCTCTCTGCTGATTTATCTCTATGACATGAAAGTGTGTTGAAG 600
DB |||||||
572 ACTCTTTGAGAGCTCTCTGCTGATTTATCTCTATGACATGAAAGTGTGTTGAAG 631
DB |||||||
601 CTGAGATACCATCTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 660
DB |||||||
632 CTGAGATACCATCTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 691
DB |||||||
661 GGATATCAAAAAGCTGTGAGAGTCCGAGTAAAGGCAAGGCAATCGGGCTC 720
DB |||||||
692 GGATATCAAAAAGCTGTGAGAGTCCGAGTAAAGGCAAGGCAATCGGGCTC 751
DB |||||||
721 ATTTTGTGATCAGGCGGTGTTTTCATTTCTGACACCTTCAATGTGCTATCTCT 780
DB |||||||
752 ATTTTGTGATCAGGCGGTGTTTTCATTTCTGACACCTTCAATGTGCTATCTCT 811
DB |||||||
781 CTCTCTCTATCAATCAATCTTATTTGGAATGATGAGGCGGCAAGATCTGAGC 840
DB |||||||
812 CTCTCTCTATCAATCAATCTTATTTGGAATGATGAGGCGGCAAGATCTGAGC 871
DB |||||||
841 CTGATGATCTGCTGACAGAGGATGATGCTCTCTCTCTCTCTCTCTCTCTCTCTCT 900
DB |||||||
872 CTGATGATCTGCTGACAGAGGATGATGCTCTCTCTCTCTCTCTCTCTCTCTCTCT 931
DB |||||||
901 TACGCTTTGTTGAGAGAGTTCCGAGAGTACTGCGCATTCTTCCACAGGCACTTG 960
DB |||||||

```
Db 932 TAGCGCTTGTGGAGAGAGTCCGGAAGTACCTGGCCACTTCTCCACAGCACTTG 991
Qy 961 CTCATGACCTGGGAGATGATCCATCTCTCTAGTGAAGAGTGGAAACACAGC 1020
Db 992 CTCATGACCTGGGAGATGATCCATCTCTCTAGTGAAGAGTGGAAACACAGC 1051
Qy 1021 TCTGTCTTCATCCACAGAGCCGGAACCTCTATTGTGTTT 1065
Db 1052 TCTGTCTTCATCCACAGAGCCGGAACCTCTATTGTGTTT 1096

RESULT 9
ABL67066
ID ABL67066 standard; DNA; 1717 BP.
XX
AC ABL67066;
XX
DT 15-MAY-2002 (first entry)
DE Thyroid cancer related gene sequence SEQ ID NO:5403.
XX
KW Human; cancer; colon; breast; ovary; oesophagus; kidney; thyroid;
KW stomach; lung; prostate; pancreas; carcinoma; antitumour; cancerous;
KW cytostatic; gene therapy; antineoplastic; Wilm's tumour; adenocarcinoma;
KW gene; ds.
XX
OS Homo sapiens.
XX
PN WO200194629-A2.
XX
PD 13-DEC-2001.
XX
PF 30-MAY-2001; 2001WO-US10838.
XX
PR 05-JUN-2000; 2000US-209473P.
PR 05-JUN-2000; 2000US-209511P.
PR 18-SEP-2000; 2000US-233133P.
PR 18-SEP-2000; 2000US-233617P.
PR 20-SEP-2000; 2000US-234009P.
PR 20-SEP-2000; 2000US-234034P.
PR 20-SEP-2000; 2000US-234052P.
PR 22-SEP-2000; 2000US-234509P.
PR 22-SEP-2000; 2000US-234567P.
PR 25-SEP-2000; 2000US-234923P.
PR 25-SEP-2000; 2000US-234924P.
PR 25-SEP-2000; 2000US-235077P.
PR 25-SEP-2000; 2000US-235082P.
PR 25-SEP-2000; 2000US-235134P.
PR 25-SEP-2000; 2000US-235280P.
PR 26-SEP-2000; 2000US-235637P.
PR 26-SEP-2000; 2000US-235638P.
PR 27-SEP-2000; 2000US-235711P.
PR 27-SEP-2000; 2000US-235720P.
PR 27-SEP-2000; 2000US-235840P.
PR 27-SEP-2000; 2000US-235863P.
PR 28-SEP-2000; 2000US-236028P.
PR 28-SEP-2000; 2000US-236032P.
PR 28-SEP-2000; 2000US-236033P.
PR 28-SEP-2000; 2000US-236034P.
PR 28-SEP-2000; 2000US-236109P.
PR 28-SEP-2000; 2000US-236111P.
PR 29-SEP-2000; 2000US-236842P.
PR 29-SEP-2000; 2000US-236891P.
PR 02-OCT-2000; 2000US-237172P.
PR 02-OCT-2000; 2000US-237173P.
PR 02-OCT-2000; 2000US-237278P.
PR 02-OCT-2000; 2000US-237294P.
PR 02-OCT-2000; 2000US-237295P.
PR 02-OCT-2000; 2000US-237316P.
PR 03-OCT-2000; 2000US-237425P.
PR 03-OCT-2000; 2000US-237598P.
PR 03-OCT-2000; 2000US-237604P.
```

```
PR 03-OCT-2000; 2000US-237606P.
PR 03-OCT-2000; 2000US-237608P.
PR 01-NOV-2000; 2000US-244867P.
PR 01-NOV-2000; 2000US-245084P.
XX
PA (AVAL-) AVALON PHARM.
XX
PI Young PE, Augustus M, Carter KC, Ebner R, Endress G, Horrigan S;
PI Soppet DR, Weaver Z;
XX
DR WPI: 2002-188264/24.
XX
PT Screening for anti-neoplastic agent involves exposing cells to a
PT chemical agent to be tested for anti-neoplastic activity, and
PT determining a change in expression of a gene of a signature gene set -
XX
PS Claim 1; SEQ ID 5403; 44pp; English.
XX
CC The present invention describes a method (M1) for screening for an
CC anti-neoplastic agent. The method involves exposing cells to a chemical
CC agent to be tested for anti-neoplastic activity, determining a change in
CC expression of at least one gene (I) of a signature gene set, where (I)
CC comprises a sequence (S) selected from 8447 sequences (given in ABL61664
CC to ABL70110), or is at least 95% identical to (S), where a change in
CC expression is indicative of anti-neoplastic activity. (I) has cytosstatic
CC activity and can be used in gene therapy. M1 can be used for screening
CC an anti-neoplastic agent, and can be used for producing a product which
CC is the data collected with respect to the anti-neoplastic agent as a
CC result of M1, and the data is sufficient to convey the chemical
CC structure and/or properties of the agent. M1 can be used in the
CC treatment of cancer such as colon, breast, stomach, lung, thyroid,
CC oesophageal, ovarian, kidney, prostate or pancreatic cancer.
CC adenocarcinoma, carcinoma, clear cell cancer, infiltrating ductal cancer,
CC infiltrating lobular cancer, squamous cell carcinoma, neuroendocrine
CC carcinoma, papillary carcinoma and Wilm's tumour.
XX
SQ Sequence 1717 BP; 434 A; 428 C; 351 G; 504 T; 0 other;

Query Match 100.0%; Score 1065; DB 24; Length 1717;
Best Local Similarity 100.0%; Pred. No. 2e-313;
Matches 1065; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 ATGACACCTCACTAGATACAGTTGAGACCTTGTGATACACATCTACTATGATGACGTG 60
Db 205 ATGACAACTCACTATATACAGTTGAGACCTTGTGATACACATCTACTATGATGACGTG 264
Qy 61 GGCCTGCTGTGAAAAAGCTGATACAGACGCTATGGCCAGTTTGCCCGCGCTG 120
Db 265 GGCCTGCTGTGAAAAAGCTGATACAGACGCTATGATGGCCAGTTTGCCCGCGCTG 324
Qy 121 TACTCCGTGTTCACCTGTGGGCGCTTGGGCAATGTGGTGGTGAATGCCATTA 180
Db 325 TACTCCGTGTTCACCTGTGGGCGCTTGGGCAATGTGGTGGTGAATGCCATTA 384
Qy 181 AAATACAGAGGCTCCGAATTTATGACCAACATCTACTGCTCAACCTGGCCATTTGGCAG 240
Db 385 AAATACAGAGGCTCCGAATTTATGACCAACATCTACTGCTCAACCTGGCCATTTGGCAG 444
Qy 241 CTGCTCTTCTGCTACACCTTCATTCCTGGATCCACTATGTCAAGGGGCAATACTGGGTT 300
Db 445 CTGCTCTTCTGCTACACCTTCATTCCTGGATCCACTATGTCAAGGGGCAATACTGGGTT 504
Qy 301 TTGGGCATGGCATGTGTAACTCCTCAAGGCTTTTATACACAGAGCTTGTACAGCAG 360
Db 505 TTGGGCATGGCATGTGTAACTCCTCAAGGCTTTTATACACAGAGCTTGTGTACAGCAG 564
Qy 361 ATCTTTTCAATATCTGCTGACATGACAGCTACTGGCCATTTGCACTGCTGTGTTT 420
Db 565 ATCTTTTCAATATCTGCTGACATGACAGCTACTGGCCATTTGCACTGCTGTGTTT 624
Qy 421 GCCCTTGAGCCCGGACGTGTCACTTTGTGTGTCATCAGACAGATGCTGTCACTGGGCGCTG 480
Db 625 GCCCTTGAGCCCGGACGTGTCACTTTGTGTGTCATCAGACAGATGCTGTCACTGGGCGCTG 684
```

OY 481 GCAGTGTAGACGCTTCCGTAATTTATCTTATAGAGACTGGAAGGTTGTTGAAGAG 540
DB 685 GCAGTGTAGACGCTTCCCTCAATTTATCTTATAGAGACTGGAAGGTTGTTGAAGAG 744
OY 541 ACTCTTTGAGAGTCTTACCAGAGATACATATAGTGGAGGATTTCCACACT 600
DB 745 ACTCTTTGAGAGTCTTACCAGAGATACATATAGTGGAGGATTTCCACACT 804
OY 601 CAGAGAAATACCATCTTCTGTCTGTTTCCCTGTCTGTCTGTATGGCATTTGCTACACA 660
DB 805 CAGAGAAATACCATCTTCTGTCTGTTTCCCTGTCTGTCTGTATGGCATTTGCTACACA 864
OY 661 GGAATCATCAAAACGCTGTAGAGTCCAGTAAATAAAGATCAAGGCAATCCGGCTC 720
DB 865 GGAATCATCAAAACGCTGTAGAGTCCAGTAAATAAAGATCAAGGCAATCCGGCTC 924
OY 721 AATTTTGTATCATGAGGCTGTTTTCATTTTCTGACACCCATCATGCTATCTCT 780
DB 925 AATTTTGTATCATGAGGCTGTTTTCATTTTCTGACACCCATCATGCTATCTCT 984
OY 781 CTTCTTCTATCATCAATCTTATTTGGAATGATGTGAGCGGAGCAAGCATCTGAC 840
DB 985 CTTCTTCTATCATCAATCTTATTTGGAATGATGTGAGCGGAGCAAGCATCTGAC 1044
OY 841 CTGTCTCATCTGTGACAGAGGTGATCGCTACTCCACTGCTGATGAACCCGGTGATC 900
DB 1045 CTGTCTCATCTGTGACAGAGGTGATCGCTACTCCACTGCTGATGAACCCGGTGATC 1104
OY 901 TACGCTTTGTTGGAGAGAGTTCCGGAAGTACCTGCGCATCTTCCACAGGCACTTG 960
DB 1105 TACGCTTTGTTGGAGAGAGTTCCGGAAGTACCTGCGCATCTTCCACAGGCACTTG 1164
OY 961 CTCATGACCTGCGGAGATACATCCATCTCTTCTAGTGAAGAGCTGGAAGAACCCAGC 1020
DB 1165 CTCATGACCTGCGGAGATACATCCATCTCTTCTAGTGAAGAGCTGGAAGAACCCAGC 1224
OY 1021 TCTGTCTCTCATCCACAGACAGAGCCGGAACCTCTATTTGTGTTT 1065
DB 1225 TCTGTCTCTCATCCACAGACAGAGCCGGAACCTCTATTTGTGTTT 1269
RESULT 10
AAD25221
ID AAD25221 standard: DNA; 1717 BP.
XX
AC AAD25221:
XX
DT 12-MAR-2002 (first entry)
XX
DE Human chemokine (C-C motif) receptor 3 (CCR3) gene #1.
XX
KW Human; chemokine (C-C motif) receptor 3; CCR3 gene; haplotyping;
KW genotyping; type IV hypersensitivity reaction; HIV-1; gene therapy;
KW human immunodeficiency virus 1; single nucleotide polymorphism; SNP;
KW chromosome 3p21.3; ds.
XX
OS Homo sapiens.
XX
FH key
FH location/Qualifiers
FT replace (92, 7)
FT /tag= a
FT /standard_name= "Single nucleotide polymorphism (SNP)"
FT variation
FT /tag= b
FT /replace (197, A)
FT /standard_name= "Single nucleotide polymorphism (SNP)"
FT CDS
FT /tag= c
FT /product= "Human CCR3 protein"
FT /note= "this region corresponds to exon 1"
FT variation
FT /tag= d
FT /standard_name= "Single nucleotide polymorphism (SNP)"

FT variation
FT replace (1256, C)
FT /tag= e
FT /standard_name= "Single nucleotide polymorphism (SNP)"
PN WO200187908-A2.
PD 22-NOV-2001.
PP 18-MAY-2001; 2001WO-US16278.
PR 18-MAY-2000; 2000US-205191P.
PA (GENA-) GENAISSANCE PHARM INC.
PI Choi JY, Kazemi A, Koshy B;
XX WPI: 2002-055681/07.
XX P-PSDB: AAE15320.
DR Isolated polymorphic variants of chemokine (C-C motif) receptor 3
PT (CCR3) gene useful for studying function of CCR3, expressing the CCR3
PT protein and to screen drugs to treat CCR3 activity-related diseases -
XX Example 1; Fig 1; 53pp; English.
XX
XX The invention relates to genetic variants of human chemokine (C-C motif)
XX receptor 3 (CCR3) gene. The invention also relates to compositions and
XX methods for haplotyping and/or genotyping the CCR3 gene in an individual.
XX Polynucleotides of the invention are useful for studying the expression
XX and function of CCR3 and in expressing CCR3 proteins for use in screening
XX candidate drugs to treat diseases related to CCR3 activity. They are also
XX used in gene therapy. The polymorphism and haplotype data is useful for
XX validating whether CCR3 is a suitable target for drugs to treat type IV
XX hypersensitivity reactions and human immunodeficiency virus (HIV)-1,
XX screening for such drugs and reducing bias cells in clinical trials of
XX such drugs. The genotyping method is useful for determining whether an
XX individual has one haplotype or haplotype pairs. The haplotyping method
XX is useful for improving the efficiency and outcome of several steps in
XX the discovery and development of drugs for treating diseases associated
XX with CCR3 activity such as type IV hypersensitivity reactions and HIV-1.
XX The present sequence is human CCR3 gene located on chromosome 3p21.3.
SQ
Sequence 1717 BP; 434 A; 428 C; 351 G; 504 T; 0 other;
Query Match 100.0%; Score 1065; DB 24; Length 1717;
Best Local Similarity 100.0%; Pred. No. 2e-313;
Matches 1065; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1 ATGACAACTCTACATAGATACAGTTGAGACCTTGGTACACATCTCATATGATGACGTG 60
DB 205 ATGACAACTCTACATAGATACAGTTGAGACCTTGGTACACATCTCATATGATGACGTG 264
OY 61 GGCCTCTCTGTGAAAAAGCTGATACAGACAGCATGATGGCCCACTTGTGCCCGCTG 120
DB 265 GGCCTCTCTGTGAAAAAGCTGATACAGACAGCATGATGGCCCACTTGTGCCCGCTG 324
OY 121 TACTCCCTGCTGTCACCTGCGGCTTGGGCAATGCTGCTGATGATCCCTCAT 180
DB 325 TACTCCCTGCTGTCACCTGCGGCTTGGGCAATGCTGCTGATGATCCCTCAT 384
OY 181 AATATACAGAGGCTCGAATTTATGACCAATCTACTCTCAACTGAGCCATTGCGAC 240
DB 385 AATATACAGAGGCTCGAATTTATGACCAATCTACTCTCAACTGAGCCATTGCGAC 444
OY 241 CTGCTCTTCTGTCACCTTCCATTTCTGATGACATATGTCAGAGGGGCAATGCGTT 300
DB 445 CTGCTCTTCTGTCACCTTCCATTTCTGATGACATATGTCAGAGGGGCAATGCGTT 504
OY 301 TTGGCCATGAGATGATGATGCTCTCTGAGGTTTATACACAGAGCTTGTACAGCGAG 360
DB 505 TTGGCCATGAGATGATGATGCTCTCTGAGGTTTATACACAGAGCTTGTGTACAGCGAG 564
OY 361 ACTTTTTCATATCTGCTGACATGACAGGTACTGCGCAATGTCCATGCTGTGTTT 420

```
|||||
Db 565 ATCTTTTATATATCTGTCGACAAATCGACAGCTGACCTGGCCATTGCTCCATGCTGTGTT 624
OY 421 GGCCTTCGAGCCCGGACCTTCACCTTTGGTGCATCACAGACATGCTGCACCTGGGCCCTG 480
Db 625 GCCCTTCGAGCCCGGACCTTCACCTTTGGTGCATCACAGACATGCTGCACCTGGGCCCTG 684
OY 481 GCAGTGTAGCAGACCTTCCTGTAATTTATCTTATAGACTGAAAGATTGTTGAAGAG 540
Db 685 GCAGTGTAGCAGACCTTCCTGTAATTTATCTTATAGACTGAAAGATTGTTGAAGAG 744
OY 541 ACTCTTTCGAGTGTCTTTTACCCAGAGATPACAGTATPAGCTGAGGCAATTTCCACACT 600
Db 745 ACTCTTTCGAGTGTCTTTTACCCAGAGATPACAGTATPAGCTGAGGCAATTTCCACACT 804
OY 601 CTGAGAAATGACCATCTTCTGTCGCTCCCTCCCTGCTGCTATAGCCCAATGCTCACA 660
Db 805 CTGAGAAATGACCATCTTCTGTCGCTCCCTCCCTGCTGCTATAGCCCAATGCTCACA 864
OY 661 GGAATCATCAAAAACGCTGCTGAGTGCCTCCAGTAAAAAAAGTACAAGCCATCCGGCTC 720
Db 865 GGAATCATCAAAAACGCTGCTGAGTGCCTCCAGTAAAAAAAGTACAAGCCATCCGGCTC 924
OY 721 ATTTTGTATCATGCGCGGTGTTTTCATTTCCTGACACCCCTACATGCTGCTATCCTT 780
Db 925 ATTTTGTATCATGCGCGGTGTTTTCATTTCCTGACACCCCTACATGCTGCTATCCTT 984
OY 781 CTTCTTCTTATCAATCCATCTTATTTGGAAATGACTGTAGGCGGAGCAAGCATCTGAGAC 840
Db 985 CTCTCTTCTTATCAATCCATCTTATTTGGAAATGACTGTAGGCGGAGCAAGCATCTGAGAC 1044
OY 841 CTGTGTCATCTGCTGTCAGAGAGTGTATGCTTACCTCCACTGCTGTCATGTAACCCGGTATC 900
Db 1045 CTGTGTCATCTGCTGTCAGAGAGTGTATGCTTACCTCCACTGCTGTCATGTAACCCGGTATC 1104
OY 901 TACGCTTTGTTGGAGAGAGGTTCCGGAAGTACCTGCGCCACTTCTTCCACAGGCACTTG 960
Db 1105 TACGCTTTGTTGGAGAGAGGTTCCGGAAGTACCTGCGCCACTTCTTCCACAGGCACTTG 1164
OY 961 CTCATGCACCTGGGCGAGATACATCCCATTCCTTCTAGTGAAGAGCTGGAAGAACACAG 1020
Db 1165 CTCATGCACCTGGGCGAGATACATCCCATTCCTTCTAGTGAAGAGCTGGAAGAACACAG 1224
OY 1021 TCTGTCTCTCATCCACAGACAGCGGAATCTCTATTGTGTTT 1065
Db 1225 TCTGTCTCTCATCCACAGACAGCGGAATCTCTATTGTGTTT 1269

RESULT 11
AAT85162
ID AAT85162 standard; cDNA; 1915 BP.
XX
AC AAT85162;
XX
DT 14-DEC-1997 (first entry)
XX
DE Human chemokine receptor 88-2B cDNA.
XX
KW Chemokine receptor 88-2B; atherosclerosis; rheumatoid arthritis;
KW tumour; asthma; viral infection; AIDS; inflammation;
KW autoimmune disease; therapy; diagnosis; leukocyte trafficking;
KW 6 protein coupled receptor; human; ss.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT CDS 362..1429
FT /*tag= a
PN WO9722698-A2.
XX
PD 26-JUN-1997.
XX
```

```
PF 20-DEC-1996; 96WO-US20759.
XX
PR 07-JUN-1996; 96US-0661393.
PR 20-DEC-1995; 95US-0575967.
XX
PA (ICOS-) ICOS CORP.
XX
PI Gray PW, Raport CJ, Schweickart VL;
XX WPI: 1997-341689/31.
XX P-PSDB: AAM27124.
DR
XX
XX New nucleic acid encoding chemokine receptors 88-2B and 88C - used
PT to modulate leukocyte trafficking, e.g. for treatment of
PT inflammation, tumours, viral infections, autoimmune diseases, etc.
XX
PS Claim 7; Page 48-50; 65pp; English.
XX
```

This sequence comprises a full-length cDNA coding for novel human chemokine receptor 88-2B (AAM27124), a G protein coupled receptor that is involved in leukocyte trafficking. The 88-2B cDNA was obtained from a macrophage cDNA library using 88-2B-specific primers. A full-length clone (see AAT85162) for chemokine receptor 88C (AAM27123) was also obtained. 88C and 88-2B cDNAs can be used to produce recombinant polypeptides in transformed host cells for use in the treatment of e.g. atherosclerosis, rheumatoid arthritis, tumours, CC asthma, viral infection, AIDS and inflammatory conditions. Nucleic acid fragments can be used to isolate genomic sequences, to detect CC alleles of the gene (for diagnosis or in gene therapy), to alter CC receptor genetics to facilitate identification of modulators and to CC produce knockout animals, and (antisense forms) to alter/study the CC genetics and expression of the receptor.

Sequence 1915 BP; 488 A; 470 C; 373 G; 584 T; 0 other;

Query Match 100.0%; Score 1065; DB 18; Length 1915;
Best Local Similarity 100.0%; Pred. No. 2.1e-313;
Matches 1065; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
OY 1 ATGACAACTGCTAGTATGAGTGTGAGACCTTGGTACCAATCTCATATATGACGTG 60
Db 362 ATGACAACTGCTAGTATGAGTGTGAGACCTTGGTACCAATCTCATATATGACGTG 421
OY 61 GGCCTCTCTGTGAAMAACTGATACAGACATGATGGCCAGTTTGGCCCGCTG 120
Db 422 GGCCTCTCTGTGAAMAACTGATACAGACATGATGGCCAGTTTGGCCCGCTG 481
OY 121 TACTCCCTGCTGTTCACTGTGGGCTCTTGGCAATGTGTGTGTATCTCTATA 180
Db 482 TACTCCCTGCTGTTCACTGTGGGCTCTTGGCAATGTGTGTGTATCTCTATA 541
OY 181 AATATAGAGAGGCTCGAATTTATGACCAATCTACCTGCAACCTGGCCATTGCGAG 240
Db 542 AATATAGAGAGGCTCGAATTTATGACCAATCTACCTGCAACCTGGCCATTGCGAG 601
OY 241 CTGCTCTTCTGTCACCTTCATTCCTGATGATCCATATGTCAGGGGCGATACTGGTT 300
Db 602 CTGCTCTTCTGTCACCTTCATTCCTGATGATCCATATGTCAGGGGCGATACTGGTT 661
OY 301 TTGGCCATGCGATGTGTAGCTCTCTGAGGCTTTTATACACAGGCTTGTACAGCAG 360
Db 662 TTGGCCATGCGATGTGTAGCTCTCTGAGGCTTTTATACACAGGCTTGTACAGCAG 721
OY 361 ATCTTTTATATATCTGTCGACAAATCGACAGTACCTGCGCATTTGCTATCTGTTT 420
Db 722 ATCTTTTATATATCTGTCGACAAATCGACAGTACCTGCGCATTTGCTATCTGTTT 781
OY 421 GGCCTTCGAGCCCGGACCTTCACCTTTGGTGCATCACAGCATGCTGCAGGGGCGCTG 480
Db 782 GGCCTTCGAGCCCGGACCTTCACCTTTGGTGCATCACAGCATGCTGCAGGGGCGCTG 841
OY 481 GCAGTGTAGCAGACCTTCCTGTAATTTATCTTATGAGACTGAAAGATTGTTGAAGAG 540
```

Db 842 GCAGTGTAGACGCTTTCGTAATTTATCTTATGAGACTGAAGAGTTGTTGAAG 901
OY 541 ACTCTTTGACAGTCTCTTTTACCAGAGATACATATATAGCTGAGGACATTTCCACT 600
Db 902 ACTCTTTGACAGTCTCTTTTACCAGAGATACATATATAGCTGAGGACATTTCCACT 961
OY 601 CTGAGAAATGACCATTTCTGTCGCTTCCCTGCTGCTGTTTANGGCAATCTGTACAC 660
Db 962 CTGAGAAATGACCATTTCTGTCGCTTCCCTGCTGCTGTTTANGGCAATCTGTACAC 1021
OY 661 GGAATCATCAAAAGCGTGTGAGTGGCCCAAGTAAAGGATACAGGCTCCGGCTC 720
Db 1022 GGAATCATCAAAAGCGTGTGAGTGGCCCAAGTAAAGGATACAGGCTCCGGCTC 1081
OY 721 ATTTTGTATCATATGAGGCTGTTTTCATTTTCTGAGACACCTACATATGTGCTATCTT 780
Db 1082 ATTTTGTATCATATGAGGCTGTTTTCATTTTCTGAGACACCTACATATGTGCTATCTT 1141
OY 781 CTCTCTTCTATCATATCATCTTATTTGAAATGACTGTGAGCGGAGCAAGCATCTGAC 840
Db 1142 CTCTCTTCTATCATATCATCTTATTTGAAATGACTGTGAGCGGAGCAAGCATCTGAC 1201
OY 841 CTGTGTATGCTGTGAGAGAGGTGATGCGCTACCTCCACTGCTGATGAACCCGGTGTATC 900
Db 1202 CTGTGTATGCTGTGAGAGAGGTGATGCGCTACCTCCACTGCTGATGAACCCGGTGTATC 1261
OY 901 TACGCGCTTTGTTGAGAGAGGTTCGGAAGTACCTGCGCCACTTCTCCACAGGCACTTG 960
Db 1262 TACGCGCTTTGTTGAGAGAGGTTCGGAAGTACCTGCGCCACTTCTCCACAGGCACTTG 1321
OY 961 CTGATGACACCTGGGAGATATCATCTCCATTTCTCTAGTGAAGACTGGAAAGCAAC 1020
Db 1322 CTGATGACACCTGGGAGATATCATCTCCATTTCTCTAGTGAAGACTGGAAAGCAAC 1381
OY 1021 TCTGTCTCTCCATCCACAGAGAGCGGGAACCTCTATTTGTTT 1065
Db 1382 TCTGTCTCTCCATCCACAGAGAGCGGGAACCTCTATTTGTTT 1426
RESULT 12
AAAF21269
ID AAF21269 standard; DNA: 3958 BP.
AC AAF21269;
XX
DT 14-MAR-2001 (first entry)
XX
DE Human low adenosine antisense oligonucleotide related sequence #2836.
XX
KW Low adenosine antisense oligonucleotide; phosphorothioate; allergy;
KW human; airway disorder; bronchoconstriction; lung inflammation;
KW surfactant depletion; respiratory; bronchodilator; antiinflammatory;
KW immunosuppressive; antiallergic; analgesic; hypotensive; cytostatic;
KW respiratory obstruction; pulmonary obstruction; impeded respiration;
KW surfactant hypoproduction; pulmonary vasoconstriction; asthma; RDS;
KW respiratory distress syndrome; pain; cystic fibrosis; allergic rhinitis;
KW pulmonary hypertension; emphysema; pulmonary transplantation rejection;
KW chronic obstructive pulmonary disease; pulmonary infection; bronchitis;
KW cancer; ss.
XX
OS Homo sapiens.
PN WO200062736-A2.
PD 26-OCT-2000.
PE 24-MAR-2000; 2000WO-US08020.
PR 06-APR-1999; 99US-0127958.
PA (UYEC-) UNIV EAST CAROLINA.
XX (NYCE/) NYCE J W.
XX

PI Nyce JW;
XX
DR WPI: 2000-679539/66.
XX
PT Low adenosine (A) content antisense oligonucleotides which do not
PT trigger adenosine receptors during metabolism, useful e.g. for treating
PT cancers and respiratory obstructions -
XX
PS Disclosure: Page 1183-1184; 1592pp; English.
XX
CC The present invention describes low adenosine (A) content antisense
CC oligonucleotides and compositions (i) comprising them. In the antisense
CC oligonucleotides the A is replaced by a 'universal' or alternative base.
CC (i) can have respiratory, bronchodilator, antiinflammatory, analgesic,
CC immunosuppressive, antiallergic, hypotensive and cytostatic activities.
CC The antisense oligonucleotides and (i) can be used to down-regulate the
CC expression and or activity of target polypeptides associated with
CC lung/respiratory disorders and malignancies, such as stimulating and
CC activating peptide factors and transmitters, transcription factors,
CC immunoglobulins and antibodies, antibody receptors, cytokines and
CC chemokines, endogenously produced specific and non-specific enzymes,
CC binding proteins, adhesion molecules and their receptors, cytokine and
CC chemokine receptors, adenosine receptors, bradykinin receptors, central
CC nervous system (CNS) and peripheral nervous and non-nervous system
CC receptors, CNS and peripheral nervous and non-nervous system peptide
CC transmitters, defensins, growth factors, vasoactive peptides and
CC receptors, binding proteins and malignancy associated proteins. The
CC antisense oligonucleotides may be used in this way to treat disorders
CC including respiratory obstruction (especially pulmonary obstruction
CC and/or bronchoconstriction) and/or lung inflammation, allergy(ies)
CC and/or surfactant hypoproduction which are associated with a disease or
CC condition selected from pulmonary vasoconstriction, inflammation,
CC allergies, asthma, impeded respiration, respiratory distress syndrome
CC (RDS), pain, cystic fibrosis (CF), allergic rhinitis (AR), pulmonary
CC hypertension, emphysema, chronic obstructive pulmonary disease (COPD),
CC pulmonary transplantation rejection, pulmonary infections, bronchitis,
CC and/or cancer. AAF18434 to AAF21543 represent human polynucleotide
CC fragments and antisense oligonucleotides used in the exemplification of
CC the present invention.
XX
SQ Sequence 3958 BP: 939 A; 1025 C; 855 G; 1138 T; 1 other:
XX
Query Match 100.0%; Score 1065; DB 21; Length 3958;
Best Local Similarity 100.0%; Pred. No. 3.2e-313;
Matches 1065; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1 ATGACAACCTCACTAGATACATTTGAGACCTTGGTACACACTCTACTATGATGACGTG 60
Db 1 ATGACAACCTCACTAGATACATTTGAGACCTTGGTACACACTCTACTATGATGACGTG 60
OY 61 GGCCCTGCTGTGAAAGAGCTGATACAGAGCAGATGAGCCCATTTGTGCCCCGCTG 120
Db 61 GGCCCTGCTGTGAAAGAGCTGATACAGAGCAGATGAGCCCATTTGTGCCCCGCTG 120
OY 121 TACTCCCTGCTGTACGTTGGGCTCTTGGCAATGTGGTGTGATGATCTCTCA 180
Db 121 TACTCCCTGCTGTACGTTGGGCTCTTGGCAATGTGGTGTGATGATCTCTCA 180
OY 181 AATATACAGAGGCTCCGATATATGACCAACATCTACCTGCTACACTGCCATTTTGGAC 240
Db 181 AATATACAGAGGCTCCGATATATGACCAACATCTACCTGCTACACTGCCATTTTGGAC 240
OY 241 CTGCTCTTCTGTCACCTTCATTTGAGATCCATATGTCAGGGGGGATTAAGTGGTT 300
Db 241 CTGCTCTTCTGTCACCTTCATTTGAGATCCATATGTCAGGGGGGATTAAGTGGTT 300
OY 301 TTTGGCCATGAGCATGTGAAGCTCTCTCAGAGGTTTATACACAGGCTTGTACAGCAG 360
Db 301 TTTGGCCATGAGCATGTGAAGCTCTCTCAGAGGTTTATACACAGGCTTGTACAGCAG 360
OY 361 ATCTTTTTCATATATCTCTGTCAGATTCAGACAGTACCTGCGCATTTGTCTGTTT 420
Db 361 ATCTTTTTCATATATCTCTGTCAGATTCAGACAGTACCTGCGCATTTGTCTGTTT 420

OY	421	GCCCTTGAGCCCGGAGCTGTCACTTTTGGTGTGTCATCCACAGATCGTCACTCGGGGGCTG	480
Db	421	GCCCTTGAGCCCGGAGCTGTCACTTTTGGTGTGTCATCCACAGATCGTCACTCGGGGGCTG	480
OY	481	GCATGTGTAGAGCTCTTCCGTAATTTATCTCTATGAGACGTGAGAGCTTTTGAAGAG	540
Db	481	GCATGTGTAGAGCTCTTCCGTAATTTATCTCTATGAGACGTGAGAGCTTTTGAAGAG	540
OY	541	ACTCTTTGCACTGCTCTTTTACCAGAGAGATACGATATATAGCTGAGGCAATTTCCACACT	600
Db	541	ACTCTTTGCACTGCTCTTTTACCAGAGAGATACGATATATAGCTGAGGCAATTTCCACACT	600
OY	601	CTGGAATGAGACATCTTCTGTCTCTGTTTCCCTCTGCTGCTGTTATGGCATCTGCTACACA	660
Db	601	CTGGAATGAGACATCTTCTGTCTCTGTTTCCCTCTGCTGCTGTTATGGCATCTGCTACACA	660
OY	661	GGAATCATCAAAAGCGTGTGAGAGTGCCCGAGTAAATAAAGATACAGGCCATCCGGCTC	720
Db	661	GGAATCATCAAAAGCGTGTGAGAGTGCCCGAGTAAATAAAGATACAGGCCATCCGGCTC	720
OY	721	ATTTTGTGATCATGAGGGGTGTTTTCATTTTCTGAGACACCCTACAAATGTGGCTATCCTT	780
Db	721	ATTTTGTGATCATGAGGGGTGTTTTCATTTTCTGAGACACCCTACAAATGTGGCTATCCTT	780
OY	781	CTCTCTTCTCTATCAATCCATCTATTTTGGAAATAGACTGTGAGCGGAGCAGACATCTGGAC	840
Db	781	CTCTCTTCTCTATCAATCCATCTATTTTGGAAATAGACTGTGAGCGGAGCAGACATCTGGAC	840
OY	841	CTGGTCATGCTGTGTGAGAGAGGTGATCGCCTACTGCCATCTGTGATGATACCCGGTATC	900
Db	841	CTGGTCATGCTGTGTGAGAGAGGTGATCGCCTACTGCCATCTGTGATGATACCCGGTATC	900
OY	901	TACGCTTTTGTGGAGAGAGGTTCCGGAATACCTGTGCCCACTTCTTCCACAGGCACCTTG	960
Db	901	TACGCTTTTGTGGAGAGAGGTTCCGGAATACCTGTGCCCACTTCTTCCACAGGCACCTTG	960
OY	961	CTCATGCACTGGGCAATATCATCCCATTCCTCTCTAGTGAAGACCTGGAAGAACCGACGC	1020
Db	961	CTCATGCACTGGGCAATATCATCCCATTCCTCTCTAGTGAAGACCTGGAAGAACCGACGC	1020
OY	1021	TCTGTCTCTCCATCCACAGAGAGCCGGAACTCTATTTGTGTTT	1065
Db	1021	TCTGTCTCTCCATCCACAGAGAGCCGGAACTCTATTTGTGTTT	1065
RESULT 13			
AAA35147			
ID	AAA35147 standard; DNA: 3958 BP.		
XX	AAA35147;		
AC	28-JUL-2000 (first entry)		
DT	Human adenosine receptor related polynucleotide 2nd SEQ ID NO:21.		
DE	Human adenosine receptor related polynucleotide 2nd SEQ ID NO:21.		
XX	Human; adenosine receptor; low adenosine antisense oligonucleotide;		
KM	phosphorothioate; impaired respiration; inflammation; allergy;		
KM	allergic disease; bronchoconstriction; inhibitor; antiinflammatory;		
KM	antiallergic; antisthmatic; cyostatic; analgesic; impaired airway;		
KM	lung disease; ischemic condition; pulmonary vasoconstriction; asthma;		
KM	respiratory distress syndrome; pain; cystic fibrosis; emphysema;		
KM	pulmonary hypertension; chronic obstructive pulmonary disease; COPD;		
KM	cancer; Leukemia; Lymphoma; carcinoma; metastasis; ss.		
XX	Homo sapiens.		
OS	Homo sapiens.		
PN	MO200009525-A2.		
XX	24-FEB-2000.		
PD	24-FEB-2000.		
XX	03-AUG-1999; 99MO-US17712.		
XX	03-AUG-1999; 99MO-US17712.		

PR	03-AUG-1998:	980S-0095212.	
XX	(UYEC-) UNIV EAST CAROLINA.		
XX			
PI	Nyce JW;		
XX			
DR	WPI: 2000-205971/18.		
XX			
PR	New antisense oligonucleotides useful for treating e.g. pulmonary		
PT	vasoconstriction, inflammation, allergies, asthma, hypertension,		
PT	bronchitis, emphysema, respiratory distress syndrome, ischemia or		
PR	cancers		
PS	Disclosure: Page 1103-1104; 1343pp; English.		
XX			
CC	The present invention describes a new composition comprising an		
CC	antisense oligonucleotide (ON) with low adenosine (up to 15%), which		
CC	targets nucleic acids involved in bronchoconstriction, allergies, and/or		
CC	inflammation. The ON can have antiinflammatory, antiallergic,		
CC	antiasmatic, cytostatic and analgesic activities. The compositions are		
CC	useful for the treatment of diseases associated with inflammation,		
CC	impacted airways, including lung disease and diseases whose secondary		
CC	effects afflict the lungs of a subject. They can be used for treating		
CC	e.g. ischemic conditions, pulmonary vasoconstriction, allergies,		
CC	asthma, impacted respiration, respiratory distress syndrome, pain, cystic		
CC	fibrosis, pulmonary hypertension, emphysema, chronic obstructive		
CC	pulmonary disease (COPD), and cancers such as leukemias, lymphomas,		
CC	carcinomas, and cancers which may metastasize to the lungs, including		
CC	breast and prostate cancer. The reduction of the adenosine content of		
CC	the ONs reduces side effects. The A-containing ONs break down with the		
CC	release of deoxyadenosine which activates adenosine receptors causing		
CC	bronchoconstriction and inflammation. AAA3213 to AAA35312 represent the		
CC	nucleotide sequences given in the sequence listing from the present		
CC	invention, which correspond to SEQ ID NO:1 to 2815, and then the last		
CC	185 sequences are also called SEQ ID NO:1 to 185, but the sequences		
CC	differ from the previously named sequences. SEQ ID NO:11 to 1680		
CC	(AAA32323 to AAA35922) are specifically claimed ONs from the present		
CC	invention. N.B. Sequences given in the disclosure of the present		
CC	invention do not match up with their corresponding SEQ ID NO: sequences		
CC	given in the sequence listing.		
XX			
SO	Sequence 3958 BP: 939 A; 1025 C; 855 G; 1138 T; 1 other:		
	Query Match	100.0%;	Score 1065; DB 21; Length 3958;
	Best Local Similarity	100.0%;	Pred. No. 3.2e-313;
	Matches 1065; Conservative	0;	Mismatches 0; Indels 0; Gaps 0;
QY	1	ATGACAACCTCCTAGATATACAGTTGAGACCTTTGGTACCACTCCTACATGATGACGCG	60
DB	1	ATGACAACCTCCTAGATATACAGTTGAGACCTTTGGTACCACTCCTACATGATGACGCG	60
QY	61	GGCCTGCTCTGTGAAAAAGCTGATACGAGACGATGATGGCCACTTTTGCCCGCGTG	120
DB	61	GGCCTGCTCTGTGAAAAAGCTGATACGAGACGATGATGGCCACTTTTGCCCGCGTG	120
QY	121	TACTCCTCGTGTACTCTGTGGGCTCTTTGGCAATGTGTGTGTATCTCTATA	180
DB	121	TACTCCTCGTGTACTCTGTGGGCTCTTTGGCAATGTGTGTGTATCTCTATA	180
QY	181	AAATACAGAGAGCTCCGAATTTATGACCAACATCTACCTCCTAACCTGGCCATTTCGGAC	240
DB	181	AAATACAGAGAGCTCCGAATTTATGACCAACATCTACCTCCTAACCTGGCCATTTCGGAC	240
QY	241	CTGCTCTTCTGTCACCCCTTCATCTGTGATGCACATATGTAGAGGGGCGATAACTGGATT	300
DB	241	CTGCTCTTCTGTCACCCCTTCATCTGTGATGCACATATGTAGAGGGGCGATAACTGGATT	300
QY	301	TTTGGCGATGGGATGTGTAAAGTCTCTTCAGGGTTTATCACACAGGCTTGTACACGCG	360
DB	301	TTTGGCGATGGGATGTGTAAAGTCTCTTCAGGGTTTATCACACAGGCTTGTACACGCG	360
QY	361	ATCTTTTATATATCCTGCTGCAATTCGACAGATGACTGGCCATTGCTCATCTCTGTTT	420

Db 361 ATCTTTTCAATAAATCTGCTGACAAATCGACAGGTACCTGGCCATTGTGCATGCTGTGTTT 420
QY 421 GCCCTTCGAGCCGGAGCTGTCACTTTTGTGTATCATCACAGCAATGCTACCTGGGCTG 480
Db 421 GCCCTTCGAGCCGGAGCTGTCACTTTTGTGTATCATCACAGCAATGCTACCTGGGCTG 480
QY 481 GCAGTGTACAGCTCTTCTGTAATTTATCTGTATGAGACTGAAGATTGTTGAAGAG 540
Db 481 GCAGTGTACAGCTCTTCTGTAATTTATCTGTATGAGACTGAAGATTGTTGAAGAG 540
QY 541 ACCTTTTGCAGTGTCTTTTACCCAGAGAGATACAGTATATAGCTGGAGGCTTTCCACACT 600
Db 541 ACCTTTTGCAGTGTCTTTTACCCAGAGAGATACAGTATATAGCTGGAGGCTTTTCCACACT 600
QY 601 CTGAGATGACCAATCTTCTGTCTGCTTCTCCCTGCTGCTTATATGGCCATCTGTACACA 660
Db 601 CTGAGATGACCAATCTTCTGTCTGCTTCTCCCTGCTGCTTATATGGCCATCTGTACACA 660
QY 661 GGAATCATCAAAACGCTGTGAGGTGCCCCAGTAAAAAAGTACAAGGCCATCCGGCTC 720
Db 661 GGAATCATCAAAACGCTGTGAGGTGCCCCAGTAAAAAAGTACAAGGCCATCCGGCTC 720
QY 721 ATTTTGTCAATCAATGCGGTGTTTTCATTTTCTGACACCCATCAATGTGCTATCTT 780
Db 721 ATTTTGTCAATCAATGCGGTGTTTTCATTTTCTGACACCCATCAATGTGCTATCTT 780
QY 781 CTCTCTTCCATCAATCCATCTTATTTGAAATGATGCTGAGGAGCAAGCATCTGAC 840
Db 781 CTCTCTTCCATCAATCCATCTTATTTGAAATGATGCTGAGGAGCAAGCATCTGAC 840
QY 841 CTGCTCATCTGTGAGAGAGGTATGCTTCCATCCATGCTGCATGAACCCGGTATC 900
Db 841 CTGCTCATCTGTGAGAGAGGTATGCTTCCATCCATGCTGCATGAACCCGGTATC 900
QY 901 TAGCCCTTTTGTGAGAGAGGTTCCGAAATACCTGCGCCACTTTTCCACAGGCACTTG 960
Db 901 TAGCCCTTTTGTGAGAGAGGTTCCGAAATACCTGCGCCACTTTTCCACAGGCACTTG 960
QY 961 CTGATGACCTGGGAGATGATCCATCTTCTGTAGAGAAAGCTGGAAGAACAGC 1020
Db 961 CTGATGACCTGGGAGATGATCCATCTTCTGTAGAGAAAGCTGGAAGAACAGC 1020
QY 1021 TCTGTCTCTCATCCACAGCAGAGCCGGAATCTCTATTTGTTT 1065
Db 1021 TCTGTCTCTCATCCACAGCAGAGCCGGAATCTCTATTTGTTT 1065

RESULT 14
AAT93601
ID AAT93601 standard: cDNA; 5099 BP.
XX
AC AAT93601:
XX
DT 07-MAY-1998 (first entry)
XX
DE Human eosinophil eotaxin receptor CC CKR3 encoding cDNA.
XX
KW Eosinophil eotaxin receptor; CC CKR3; human; treatment: dermatitis;
KW atopic condition; allergic rhinitis; conjunctivitis; bronchial asthma;
KW beta-chemokine receptor; viral infection; ss.
XX
OS Homo sapiens.
XX
FH key location/Qualifiers
FT misc_feature 1..3586
FT /*tag- a
FT /note- "5' genomic DNA flanking sequence"
FT CDS 3587..4654
FT /*tag- b
FT /product- "human eosinophil eotaxin receptor"
FT misc_feature 4655..5099
FT /*tag- c
FT /note- "terminator region"

XX
XX MO9741154-A1.
PN 06-NOV-1997.
PD 24-APR-1997; 97WO-US06568.
PF 17-JAN-1997; 97GB-0000894.
PR 26-APR-1996; 96US-0016158.
PR 26-APR-1996; 96US-0017113.
XX
XX (MERI) MERCK & CO INC.
XX
XX Daugherty BL, Demartino JA, Siciliano SJ, Springer MS;
XX WPI: 1997-549685/50.
XX P-PSDB; AANJ1850.
XX
XX New isolated human eosinophil eotaxin receptor - used to develop
XX products for treating and preventing atopic conditions e.g. allergic
XX rhinitis, dermatitis, conjunctivitis and bronchial asthma
XX
XX
XX Claims 12, 13, 14; Pages 16-20; 51pp; English.
XX
XX This cDNA encodes a human eosinophil eotaxin receptor. This 5099 base
XX pair sequence comprises a 1065 base pair open reading frame encoding a
XX 355 amino acid eosinophil eotaxin receptor protein, flanked by a 5'
XX genomic DNA sequence and a 3' terminator region. This novel eosinophil
XX eotaxin receptor is a human beta-chemokine receptor designated CC CKR3.
XX Agents which bind to this eosinophil eotaxin receptor can be used for
XX the treatment and prevention of atopic conditions such as allergic
XX rhinitis, dermatitis, conjunctivitis and bronchial asthma. Agents which
XX block this eosinophil eotaxin receptor can be used to prevent viral
XX infection in healthy individuals and slow or halt viral progression
XX in infected patients.
XX
SQ Sequence 5099 BP; 1388 A; 1171 C; 1013 G; 1527 T; 0 other;
Query Match 100.0%; Score 1065; DB 18; Length 5099;
Best Local Similarity 100.0%; Pred. No. 3, 6e-313;
Matches 1065; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 ATGACAACCTCATAGATAGATGAGACCTTTGTACACATCTTATGATGACGTG 60
Db 3587 ATGACAACCTCATAGATAGATGAGACCTTTGTACACATCTTATGATGACGTG 3646
QY 61 GGCCTGCTGTGAAAAAGCTGATPACAGACACTGATGGCCCAAGTTTGCCCCGCTG 120
Db 3647 GGCCTGCTGTGAAAAAGCTGATPACAGACACTGATGGCCCAAGTTTGCCCCGCTG 3706
QY 121 TACTCCCTGTGTTCACTGTGGGCTCTTGGCAATGTGGTGGATGATCTCATTA 180
Db 3707 TACTCCCTGTGTTCACTGTGGGCTCTTGGCAATGTGGTGGATGATCTCATTA 3766
QY 181 AAATACAGAGGCTCCGAATTTATGACCAACATCTACTGCTCAACCTGGCCATTTGGAC 240
Db 3767 AAATACAGAGGCTCCGAATTTATGACCAACATCTACTGCTCAACCTGGCCATTTGGAC 3826
QY 241 CTGCTCTCTCTGTCACCTTCCTTCCATTTGTGATCCACTATGTCAGGGGCAATACTGGGTT 300
Db 3827 CTGCTCTCTCTGTCACCTTCCTTCCATTTGTGATCCACTATGTCAGGGGCAATACTGGGTT 3886
QY 301 TTGGCCATGAGCATGTGTAAAGTCCCTCAGGGTTTATACACAGGCTGTACAGGAG 360
Db 3887 TTGGCCATGAGCATGTGTAAAGTCCCTCAGGGTTTATACACAGGCTGTACAGGAG 3946
QY 361 ATCTTTTCAATAATCTGCTGACAAATGACAGGTACCTGGCCATTGCTATGCTGTGTT 420
Db 3947 ATCTTTTCAATAATCTGCTGACAAATGACAGGTACCTGGCCATTGCTATGCTGTGTT 4006
QY 421 GCCCTTCGAGCCGGAGCTGTCACTTTTGTGTATCATCACAGCAATGCTGACCTGGGCTG 480
Db 4007 GCCCTTCGAGCCGGAGCTGTCACTTTTGTGTATCATCACAGCAATGCTGACCTGGGCTG 4066

